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Abstract 
Background: A novel, isothermal nucleic acid amplification method, RT-LAMP, presents 
potential for nucleic acid amplification-based diagnostics in resource-limited settings. Low-
cost HIV-1 viral load monitoring will improve access to ART for HIV-1-infected individuals 
present in settings where on-site viral load testing is unavailable.  
Aim: The aim of this dissertation was to develop an RT-LAMP HIV-1 viral load assay by 
combining the RT-LAMP reaction with colorimetric amplification detection by hydroxy-
naphthol blue dye.  
Methods: Different approaches for HIV RNA extraction from patient plasma and culture 
supernatant were studied to obtain template for RT-LAMP. Reaction products for 4 different 
RT-LAMP primer sets were analysed using agarose gel electrophoresis and restriction 
digestion. 
Results: The first 3 primers sets produced persistent off-target amplification. The fourth 
primer set, designed against culture supernatant DU179, produced a target-specific colour 
change from violet to blue after 1 hour, following optimisation of amounts of Mg2SO4 and 
AMV RT. Further studies showed HNB detection sensitivity to template copy number.  
Conclusions: Initial reaction conditions pertaining to an RT-LAMP based, colorimetric HIV-1 
viral load assay were established. Further work is required to determine the reaction duration 
at which the colour change represents a viral load of ≥1000 copies HIV RNA per ml plasma. 
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Chapter 1 
1.1. Introduction 
Resource-limited regions of the world are often beset with a lack of basic health care 
resources, as effective health providers require sustained and maintained infrastructure, 
skilled individuals and means to communicate with the communities they serve. It is, 
therefore, understandable that the regions of the globe most affected by the HIV-1 
pandemic are indeed resource-limited. In this regard, sub-Saharan Africa, located in the 
developing world, is host to the largest population of HIV-1 infected individuals, 
comprising 69% of the globe’s new HIV infections and 70% of the world’s AIDS-related 
deaths (UNAIDS, 2012).  
 
Although the figures remain staggering, a 25% decrease has been recorded in new sub-
Saharan infections since 2001 (UNAIDS, 2012). The main elements attributing to this 
success have been improved access to anti-retroviral therapy (ART). This has certainly 
been an important approach, since individuals with higher viral loads are at increased risk 
of transmitting the virus. Moreover, infected individuals who display positive treatment 
outcomes, through viral load suppression, lower their risk of transmitting the virus 
(Montaner et al., 2010). This is further displayed at the population level as sero-negative 
individuals inhabiting regions characterised by good ART-coverage are significantly less 
likely to contract the disease (Montaner et al., 2010; Tanser et al., 2013). Improved ART 
has also reduced the number of AIDS related deaths in South Africa (Walensky et al., 
2008; Herbst et al., 2009).  
 
The HIV-disease prognosis of a treated individual is subject to multiple factors, such as the 
risk of development of resistance to treatment (Deeks, 2003) and the risk of treatment 
interruption due to lack of adherence on part of the patient (Nischal, Khopkar and Saple, 
2005), or problems surrounding provision of the drugs. The individual response to ART is 
highly unpredictable and therefore needs frequent monitoring. It thus follows that disease 
progression-monitoring plays an important role in combating the HIV pandemic. The main 
events occurring within the HIV disease progression timeline are: initiation of therapy, 
monitoring of virologic suppression, identifying virologic failure leading to ART regimen 
switching, identifying virologic failure leading to development of full blown AIDS and/or 
mortality. As long as the continued high financial and skills requirements of the current 
disease progression-monitoring methodologies prevent individuals in resource-limited 
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regions from being identified for entry into a treatment program (Stevens and Marshall, 
2010; WHO, UNICEF and UNAIDS, 2010), prevention of transmission and mortality is 
impeded.  
 
1.2. Literature Review 
1.2.1. Methods of disease progression-monitoring 
Across the spectrum of human diseases, diagnostic tests and follow-up methodologies are 
based on identification of symptoms and clinical signs of adverse health, as well as 
measurement of biomarkers (Mayeux, 2004; Jain, 2010). The observation of symptoms, 
while a common starting point for diagnosis, requires further confirmatory tests. This is 
because symptoms are often synonymous between varieties of diseases. Biomarkers are, 
therefore, required to identify the specific disease and causal agent. Often specific to stages 
of a disease, they have a primary role in disease progression-monitoring (Mayeux, 2004; 
Jain, 2010; Mamas et al., 2011). Here, a biomarker is by definition a biological signature 
associated with disease, often occurring at the molecular level (Mayeux, 2004; Jain, 2010; 
Mamas et al., 2011). Common biomarkers for disease include antibodies (Ballew et al., 
2013), the presence or absence of intercellular signalling molecules (Lane et al., 2007), 
hormones (Linkov, Yurkovetsky and Lokshin, 2009), and changes in levels of molecules 
or cells (Mellors et al., 1997) (Jain, 2010). The identification of a biomarker involves 
identifying a significant difference in the particular marker when comparing a diseased and 
a healthy individual.  
 
Global and national conventions recognise 2 main biomarkers used to monitor HIV disease 
progression: the CD4 cell count and the HIV-1 viral load. These biomarkers are 
implemented with specific guidelines for their use, whereby a CD4 count below 350 
cells/ml is used to identify individuals for ART initiation (WHO, UNICEF and UNAIDS, 
2010; Department of Health, 2013). Following treatment initiation, viral load is then 
recommended to identify response to treatment, specifically by identifying a change from 
undetectable (below 400 copies/ml) to above 1000 copies HIV-1 RNA/ml plasma 
(Department of Health, 2013).  
 
The CD4 count is determined by measuring the number of cell-bound CD4 receptors in a 
fixed volume of blood using fluorescence activated cell sorting (FACS) (Zijenah et al., 
2006). This is because cells bearing the CD4 receptor are rapidly depleted following HIV 
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infection (Fauci, 1988). Plasma viral load is a measure of circulating virus particles in a 
fixed volume of blood plasma, and specifically quantifies viral RNA stored inside the virus 
protein coat of infective viral particles. Because RNA degrades very easily, it is unlikely 
that RNA not shielded by a protein coat will be viable or present in viral load tests, which 
means the quantified RNA specifically represents circulating viral particles (Mellors et al., 
1997), and at a ratio of 1 copy of viral RNA per particle. Viral particles circulating in the 
blood represent a population of viruses available to further infect and so deplete CD4 cells. 
It is expected therefore to be a reliable predictor of transmission risk and progression to 
AIDS. Although extracellular RNA is measured, the circulating population also provides 
information about the host’s intracellular response to treatment. This is because viral 
particles cannot replicate outside the host’s cells. If the number of circulating viral particles 
is increasing, this means there is active viral replication occurring intracellularly and as 
such would be indicative of ART failure. CD4 cell count and HIV viral load complement 
each other via an inverse relationship (Mellors et al., 1997), as there is an indirect 
correlation between the amount of replicating virus in the blood and the CD4 count. When 
viral replication is supressed, such as by the action of ART, the host is able to regenerate 
the CD4 cell supply. Should the virus begin rapidly replicating again, known as virologic 
failure, the CD4 cells will once again become depleted.  
 
This inverse relationship is not however direct, as each marker differs in viability for 
disease progression-monitoring. The strength of the CD4 count is in its value to predict 
progression to AIDS disease (Korenromp et al., 2009) and is therefore the main criteria 
used to identify patients eligible to start ART. Still, CD4 count is not affected exclusively 
by HIV infection, as any state of disease can lower the count at a given moment, as well as 
emotional stress (Remor et al., 2007), pregnancy (Chama et al., 2009), smoking (Tollerud 
et al., 1989) and treatment such as cancer chemotherapy (Lissoni et al., 2009; Gunturu et 
al., 2010).  
 
Fluctuations in CD4 cell count have been observed in situations of both viral suppression 
and treatment failure; Rawizza et al., 2011) and therefore CD4 count is not a reliable 
predictor of virologic failure (Badri, Lawn and Wood, 2008). The reduction in CD4 cells in 
response to treatment failure is delayed (Badri et al., 2008; Keiser et al., 2009). In some 
cases, decreases below clinically relevant thresholds, such as below 200 or 350 cells/mm
3
, 
are evident despite an undetectable viral load (Jourdain et al., 2013). Previously, an 
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undetectable viral load was defined as a viral load falling below the detection limit of the 
relative viral load testing platform, commonly between 40-400 copies HIV RNA per ml 
plasma (Abravaya et al., 2003; Schumacher et al., 2007). This has been updated to below 
1000 copies, which is a more standardised threshold, based on what is considered to have 
clinical relevance to disease progression (Department of Health, 2013). There is a level of 
discordance between CD4 count and viral load (Korenromp et al., 2009), which is 
problematic when treated individuals are managed solely by CD4 count. This is because 
the clinical relevance of a change in CD4 count varies depending on viral load response, 
which, if indicative of virologic failure, will translate into progression to AIDS or death, 
regardless of the CD4 count (Tan et al., 2008). Increased viral load has compared well with 
depleted CD4 cell count and clinical observations (Griffith et al., 1997; Mellors et al., 
1997), for example, co-infection with sexually transmitted infections (STI’s) (Nkengasong 
et al., 2001). Therefore it follows that viral load is a stronger disease progression marker 
than CD4 count (Mellors et al., 1997; Jourdain et al., 2013). 
 
Viral load testing by RT-PCR 
Platforms for RNA quantification and nucleic acid testing in general are complex. Viral 
load testing is mainly performed by real time reverse transcription – polymerase chain 
reaction (RT-PCR) assays (Rouet et al., 2008). The most common of these assays is the 
Roche Cobas Taqman HIV-1 and Abbott HIV Real Time assay. These assays provide 
absolute viral load counts as copies of RNA/ml plasma (Abravaya et al., 2003; 
Schumacher et al., 2007). Utilising what is known as probe hydrolysis, the fluorescent 
signal of a labelled nucleic acid probe is quenched when it hybridises to the RT-PCR 
amplicons (Abravaya et al., 2003; Schumacher et al., 2007). The fluorescence is monitored 
in real time and used to determine how early a sample reaches the exponential phase of 
amplification, which is then correlated to viral load (Abravaya et al., 2003; Schumacher et 
al., 2007).  
 
Sensitive HIV RNA quantification requires that primers and probes target highly 
conserved viral gene regions, that is, regions of the viral genome which are essential to 
infectivity. The HIV replication process lacks proof-reading capacity which means 
mutations are generated in the viral genome at every round of replication leading to high 
levels of genetic heterogeneity in infected individuals, which could lead to underestimated 
viral load if the employed primers and probes cannot hybridise with these mutated regions 
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(Wojewoda et al., 2013). The Roche and Abbot assays detect targets in the integrase region 
of the Pol gene (Abravaya et al., 2003) and p24 region of the Gag gene (Schumacher et al., 
2007) (Fig. 1.1.). These 2 regions are the most conserved regions of the HIV-1 genome 
following the long terminal repeat (LTR) region. Both genes are essential for virus 
infectivity. The integrase gene codes for the integrase enzyme which assists the integration 
of proviral DNA into the host genome (Craigie, 2001). The p24 region codes for the 
protein which forms the capsid around the genomic RNA within the viral particle (Freed, 
1998). The LTR region is limited as a target as only a small portion of it is included in the 
RNA genome, while the rest of the LTR region is generated within the provirus following 
the reverse transcription phase of the HIV replication cycle (Cullen, 1991).  
Figure 1.1 Map of the HIV-1 genome showing the p24 region of the Gag gene and the integrase 
region of the Pol gene, classic targets of nucleic acid-based viral load testing (Los Alamos 
Database, 2012). 
 
Both assays boast excellent performance and sensitivity in terms of copy number detection 
limit and positive predictive value (Khopkar et al., 2013; Wojewoda et al., 2013). The 
Abbott assay has the highest sensitivity of the two with 100% sensitivity and the Cobas 
assay follows at 95%, both at a detection limit of 40 copies (Abravaya et al., 2003; 
Schumacher et al., 2007). They are also very specific, failing to detect common co-
infections such as HBV (Khopkar et al., 2013; Xu et al., 2008), but a number of practical 
drawbacks make them unsuitable to resource limited settings. Assay workflow includes a 
variety of steps totalling 5-6 hours (Klein et al., 2003). Massive automated nucleic acid 
extraction devices and thermocyclers with real-time product detection are used, making the 
technique very expensive, difficult to operate, requiring regular maintenance and 
calibration. The delicate reagents, such as fluorescently-labelled probes and internal 
controls, require cold-storage, further increasing cost and complexity (Promso et al., 2006; 
Rouet et al., 2008).  
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Viral load testing is performed at centralised laboratories or hospitals, often situated days 
away from primary health care clinics (Rouet et al., 2008; Fatti, Grimwood and Bock, 
2010). Primary care clinics aim to provide health care within close proximity to where 
people reside. However, they consist of very limited infrastructure and are staffed by a few 
nurses (Boulle et al., 2010) who perform both medical and administrative tasks (Ganesan-
Moothusamy and Naidoo, 2013).  In some settings, viral load testing does not take place at 
all (Boyles et al., 2011; Ganesan-Moothusamy and Naidoo, 2013). Instead CD4 counts 
carried out off site, combined with WHO clinical staging are used to initiate patients for 
ART (Ganesan-Moothusamy and Naidoo, 2013). However, WHO recommendations are 
less sensitive than HIV-1 RNA viral load for identifying individuals eligible for treatment 
and those undergoing treatment failure (Kamya et al., 2004; Sen et al., 2011). Some 
patients do not receive a result and a significant proportion of them are lost to follow up 
(Ganesan-Moothusamy and Naidoo, 2013). A loss-to-follow-up patient is a patient who 
enters the treatment program but does not return to the clinic thereafter (Boulle et al., 2010; 
Fatti et al., 2010). Since CD4 count is not as accurate as viral load, the majority of sub-
Saharan HIV-infected individuals are receiving sub-optimal disease progression-
monitoring (Mee et al., 2008).  
 
1.2.2. Strategies for low-cost monitoring 
The need for low-cost, simple alternatives is urgent. There are generally 2 approaches to 
identifying progression-monitoring strategies suitable to resource-limited settings: 1) 
identifying new biomarkers and 2) developing new techniques for measuring current 
biomarkers.  
 
1.2.2.1. Alternative biomarkers 
Disease progression-monitoring is multifaceted, including identifying the need for 
treatment initiation, predicting and tracking response to treatment, and predicting mortality 
at a clinical sensitivity and diagnostic specificity of 80-100%. Clinical sensitivity indicates 
how many individuals positive for any of the above disease states were identified by the 
relative marker, while diagnostic specificity indicates how many individuals identified as 
positive were truly positive (Bustin et al., 2009). A highly relevant marker would 
contribute to all aspects of progression-monitoring, whereas other sub-optimal markers 
may only be useful for monitoring isolated disease stages (Jain, 2010). Commonly 
investigated surrogate markers include total lymphocyte count (Mahajan, Hogan and 
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Snyder, 2004), β-2 microglobulin (Nkengasong et al., 2001), blood haemoglobin (Hb) 
(Jerene et al., 2006) and body mass index (BMI) (Maas et al., 1998) (Fig. 1.2). Further 
markers can include presence of co-infections (Nkengasong et al., 2001) and adherence to 
treatment (Cambiano et al., 2010). The merits of each of these markers are discussed 
below. 
 
Figure 1.2 The role of four alternative biomarkers in HIV disease progression-monitoring. 
Biomarkers include haemoglobin levels (Hb), body mass index (BMI), total lymphocyte count 
(TLC) and β-2 microglobulin (β-2). Suitability of biomarkers to resource-limited settings were 
defined as highly relevant (green) or sub-optimal (orange). 
 
A) Full blood count and total lymphocyte count 
Full blood count (FBC) is a low-cost routine blood test from which the total lymphocyte 
count is easily derived. A full blood count will provide the total white blood cell count, 
from there the total lymphocyte count is calculated as percentage lymphocytes multiplied 
by the white blood cell count, multiplied by 1000 (MediaLab Inc.). It is also a logical 
marker as the total lymphocyte count (TLC) inherently includes the CD4 count. The 
simplicity of measuring TLC makes it a promising surrogate marker. The reported 
sensitivity for using absolute TLC to predict clinically significant CD4 count thresholds of 
200 and 350 cells/mm
3
 are as low as 71% and 60% respectively (Chaudhary et al., 2008). 
A better approach is to monitor changes in TLC, instead of using absolute values, to 
predict CD4 count changes which has a sensitivity of 80-90% (Florence et al., 2004; 
Mahajan et al., 2004; Chaudhary et al., 2008) with exception to CD4 count below 200 
cells/mm
3
 (Spacek et al., 2003). The clinical significance of this is that a lack of increase in 
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TLC following more than a month of treatment predicts death, although it is not sensitive 
enough to identify patients at risk of immediate death (Jerene et al., 2006). Even so, TLC 
does not correlate as well with viral load (Mahajan et al., 2004) and this may be due to the 
existing discrepancy between CD4 count and viral load. TLC also varies from individual to 
individual, further lowering sensitivity as a surrogate marker in isolation (Mahajan et al., 
2004). The prognostic value of TLC is therefore improved when combined with the 
individuals’ WHO stage (Jerene et al., 2006; Chaudhary et al., 2008) or with white blood 
cell count and CD4 count at treatment initiation (Azzoni et al., 2012). Although the main 
advantage of this test is the minimal cost, specimens are nevertheless still sent to reference 
laboratories for result interpretation (Ganesan-Moothusamy and Naidoo, 2013), increasing 
turn-around-time. 
 
B) β-2 Microglobulin and immune activation  
Immune activation refers to the rapid increase in circulating lymphocytes and cytokines in 
response to infection (Cossarizza et al., 2012). A positive feedback exists in HIV infection 
whereby an increase in viral load, interpreted as increased infection leads to immune 
activation, following that immune activation aids HIV replication due to the activation of 
CD4 cells (Cossarizza et al., 2012). It can therefore be assumed that markers of immune 
activation are multi-functional in HIV disease progression-monitoring by identifying 
increased viral load which points to treatment failure while simultaneously predicting 
disease progression due to CD4 depletion following increase viral replication. β-2 
microglobulin is a marker of immune activation for which increased levels are associated 
with increased viral load (Nkengasong et al., 2001; Cossarizza et al., 2012). A range of 
2.9-5 mg/L predicts death in ART-naïve patients (Nyamweya et al., 2012). Measurement 
can be performed simply by nephelometry (Savès et al., 2001). A nephelometer measures 
the scatter of light in liquid through which antigens and antibodies are passed, allowing for 
the detection of antibody-antigen immune-complexes. Even though β-2 microglobulin 
levels do change in response to ART, the correlation is still below 90% clinical sensitivity 
and specificity for predicting virologic failure, as well as with predicting disease 
progression (Chaudhary et al., 2008), which compares sub-optimally with the statistically 
significant correlation between HIV-1 RNA viral load and these 2 disease stages (Mellors 
et al., 1997). Another means of identifying immune activation includes monitoring the 
presence of acute co-infections, such as symptoms of STI’s and/or the presence of 
inflammation (Nkengasong et al., 2001), although such a strategy may be a more 
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qualitative than a quantitative means of monitoring disease. The advantage of immune 
activation is that it is a very accurate means of predicting increased viral load, however 
markers of immune activation such as β-2 microglobulin lack sensitivity (Mellors et al., 
1997) since an ideal clinical sensitivity should be above 90%. 
 
C) Haemoglobin (Hb) 
The investigation into Hb as an HIV disease progression marker arose from the high 
incidence of anaemia, defined as Hb less than 12 g/dL (Obirikorang and Yeboah, 2009), 
observed in HIV positive individuals (Semba et al., 2002). Hb levels are tested on a rapid, 
finger-prick, point of care device and are already performed frequently at primary health 
care clinics. While levels correlate significantly well with CD4 count, dropping below 
healthy ranges (12.0-18.0 g/dL) with the clinically relevant decline in CD4 count (Semba 
et al., 2002; Obirikorang and Yeboah, 2009), this only translates into a clinical sensitivity 
of around 50% in identifying individuals for ART initiation (Sen et al., 2011). Decline in 
Hb in pre-ART anaemic individuals predicts a negative prognosis of progressing to AIDS 
(Jerene et al., 2006), while individuals who develop anaemia during the course of HIV 
infection have a mortality rate of 37%, in both pre-ART non-anaemic and anaemic 
individuals (Semba et al., 2002). Following successful ART treatment, individuals anaemic 
at treatment initiation exhibit significant recovery from anaemic levels of Hb (Johannessen 
et al., 2011), showing that routine Hb testing can also play a role in monitoring treatment 
response.  
 
D) Body mass index (BMI) and obesity 
Body mass index (BMI calculated as weight divided by height squared, measured in 
kg/m
2
) is by far the simplest biological characteristic to monitor. The clinical relevance of 
a decline or increase in BMI depends on identifying a baseline BMI (van der Sande et al., 
2004), that is the BMI of an individual at the start of treatment. This is because weight loss 
can be considered pathological if it equates to a BMI less than 18 kg/m
2
 (Malvy et al., 
2001; van der Sande et al., 2004) or is more than 10% unintentional weight loss (Maas et 
al., 1998) or can be indicative of a healthy lifestyle change for a previously obese 
individual. Obesity at baseline is associated with faster progression to disease, contributing 
to CD4 cell depletion (Crum-Cianflone et al., 2010). Alternatively, a decline in a treated 
patient with a low baseline BMI suggests poor response to treatment (Jerene et al., 2006) 
this does not specifically correlate to viral load (Maas et al., 1998). Prior to improved 
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longevity as a result of improved access to treatment, also known as the pre-ART era, low 
BMI, indicative of wasting, has been a strong predictor of progression to AIDS (Maas et 
al., 1998; Malvy et al., 2001). Wasting is considered generally to be a good predictor of 
all-cause mortality and is also useful as an ART-eligibility criterion (Maas et al., 1998; van 
der Sande et al., 2004).  
 
E) Clinical presentation and co-infections 
The most obvious predictor of disease progression is the presentation of disease as it points 
to significant immune-compromise, which is suggestive of progression to AIDS. WHO and 
the department of health include the presence of co-infection with either TB or Hepatitis B 
as part of the guidelines for identifying individuals eligible for ART (WHO, UNICEF and 
UNAIDS, 2010; Department of Health, 2013). Since increased viral load is associated with 
disease progression, it is unsurprising that the presence of multiple STI’s is associated with 
increased viral load, as high as 2.5 fold (Nkengasong et al., 2001). Such infections 
fortunately have very distinct clinical presentations that aid immediate diagnosis and can 
therefore be easily included in a resource-limited monitoring strategy. Other co-infections 
common to the HIV-positive population such as Hepatitis B and C (HBV, HCV) and TB 
show potential to predict mortality and point to immune suppression (Chen et al., 2009; 
Glynn et al., 2010). However, clinical presentation of advanced co-infection induced 
disease, such as active T.B. is an indication of advanced progression to AIDS (Ong et al., 
2008), which is too late a stage to predict virologic failure or disease progression, possibly 
due to discordant or delayed CD4 response to virologic failure. Still, presence of advanced 
disease is a very important indicator of risk of mortality.  
 
F) Adherence to treatment 
Standard ART consists of the combination of at least three antiretroviral drugs. ART 
regimens administered in South Africa consist of a variety of anti-retroviral drugs 
including Nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside Reverse 
Transcriptase inhibitors (NNRTI) (Department of Health, 2013). The required daily 
consumption of multiple pills along with reported adverse side-effects such as nausea and 
appetite loss make adherence to treatment a challenge. Treatment interruption can proceed 
to treatment failure due to the propagation of resistant viral strains during treatment lapse. 
Therefore, monitoring patient adherence can be used to monitor disease progression 
(Townsend et al., 2007; Bisson et al., 2008; Cambiano et al., 2010). Virologic failure can 
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be predicted at a sensitivity of 80% by identifying patients who adhered to less than 90%-
100% of their treatment over a 6 month period or 90% over a 12 month period of 
monitoring adherence (Bisson et al., 2008). The advantage of the use of adherence 
monitoring is it predicts virologic failure at a specificity of 88-98% (Bisson et al., 2008) 
and is performed simply by ART prescription data capture, but the major drawback is that, 
when applied in a diagnostic context, the turn-around-time is at least 6 months and 
therefore cannot identify treatment failure immediately. 
 
Diagnostic accuracy of markers 
Measurements for most of these markers are easily obtainable at the point of care. Each 
marker shows statistically significant correlations (direct or inverse) with CD4 count 
and/or viral load (Florence et al., 2004). But when these correlations are applied in a 
diagnostic context both sensitivity and specificity is lacking. Apart from Hb, they fail to 
approach the prognostic superiority of the CD4 count and HIV viral load. Even so, in the 
absence of CD4 count and viral load measurements, the value of these markers in assessing 
HIV disease progression is strengthened when combined. BMI for example, affects Hb 
levels (Semba et al., 2002) and therefore one could expect that a decline in Hb will have 
different implications when comparing individuals with healthy and unhealthily low 
BMI’s. Similarly, the use of Hb measurements aids in TLC prediction of CD4 count below 
200 cells/mm
3
 (Spacek et al., 2003). Such markers may therefore be applied 
algorithmically as a low cost monitoring strategy (Azzoni et al., 2012). 
 
1.2.2.2. Alternative viral load assays and point-of-care strategies 
Given the superiority of HIV-1 viral load in HIV disease progression-monitoring, another 
approach to improving monitoring in resource-limited settings is the development of 
simpler, cheaper and faster methodologies of viral load measurement. The long terminal 
repeat (LTR) assay (Drosten et al., 2006), reverse transcriptase activity assay (Jennings et 
al., 2005) and p24 ELISA (Schupbach et al., 1996) are examples of cheaper viral load 
assays which have already been developed.  Pooled viral loads (Smith et al., 2009), and the 
use of dried-blood-spots (Johannessen et al., 2009), are developing technologies that aim to 
ease the challenge of centralised real time RT-PCR testing. Reverse transcription loop-
mediated isothermal amplification (RT-LAMP) on the other hand is an example of a novel 
nucleic acid technology that may be comparable to real-time RT-PCR nucleic acid test 
(Notomi et al., 2000). 
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A) LTR assay  
This assay is a one-step real time RT-PCR assay. While this assay compared well with the 
commercial kits, it still relies on the use of the real-time thermocycler (Fibriani et al., 
2012). While simultaneous cDNA synthesis and amplification reduces the cost of reagents, 
complexity and turn-around-time (Drosten et al., 2006), there is no simple read out, 
reagents include multiple probes and an internal control (Fibriani et al., 2012) rendering 
this assay unsuitable for remote regions. It may be considered a good alternative option in 
the context of centralised laboratories as it appears to be superior in multiple subtype 
detection, cheaper than real-time PCR and also ultrasensitive, with a detection limit of 50 
copies/ml (Drosten et al., 2006) and over 90% sensitivity and specificity for identifying 
treatment failure as a HIV-1 RNA viral load above 500 copies/ml (Fibriani et al., 2012).  
 
B) RT activity assay 
Reverse transcriptase (RT) activity assays aim to quantify the amount of circulating virus 
by measuring the activity of the virus’ inherent RT (Jennings et al., 2005; Stevens et al., 
2005; Mine et al., 2009). The assay involves immobilizing RT and quantifying DNA 
hybrid products using labelled deoxy-uridine tri-phosphates (dUTPs) (Jennings et al., 
2005; Stevens et al., 2005; Mine et al., 2009). Performance and result interpretation of such 
an assay is somewhat complex; and the 2-day turn-around-time is highly unfavourable 
(Iqbal et al., 2007) and contributes to high rates of loss as patients do not return to the 
clinic for their results. 
 
C) p24 Enzyme-linked immunosorbent assay (ELISA) 
The p24 enzyme-linked immunosorbent assay (ELISA), which quantifies viral p24 antigen 
in plasma (Schupbach et al., 1996; Stevens et al., 2005; Patton et al., 2006), is simple, and 
comparable to the current PCR tests, with a 100% sensitivity for samples of above 50 000 
HIV RNA copies/ml (Jennings et al., 2005). It is not limited by genetic diversity, which 
would be a limitation in a PCR-based test, since it measures the actual protein levels 
(Patton et al., 2006). The assays can be modified to accommodate use of dried blood spots 
(DBS) as well as fluid (Patton et al., 2006). However, despite inexpensive reagents, which 
provide a cost advantage, the regular assay takes approximately 2 days and requires a 
reasonably skilled laboratory technician to monitor multiple incubation steps and 
quantification by spectrometry (Patton et al., 2006). Also, the lower detection limit of 50 
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000 copies HIV is 50 times higher than the clinically relevant viral load threshold defining 
virologic failure.  
 
D) Pooled viral load testing 
Pooled viral load testing is a cost-reducing strategy for resource-limited viral load 
monitoring, involving performing a single viral load test on pooled patient samples of a 
particular infected population. It is performed most effectively, if the tested population has 
a predicted low risk of virologic failure (van Zyl et al., 2011). This is an example of how a 
combination of the prior discussed clinical biomarkers can complement RNA viral load 
testing. The pooling is done in 2 ways, either by pooling 5 samples or by a matrix with the 
capacity to pool 100 samples, where a single sample may be pooled more than once (Smith 
et al., 2009; van Zyl et al., 2011). Within the pools, individual samples are also tested to 
help identify which samples contribute most to the viral load total measured for the pool, 
thereby identifying individuals for treatment failure without having to test those who are 
likely to have a low viral load (Smith et al., 2009; van Zyl et al., 2011). In this manner 
costs are reduced, as the number of viral load assays performed can be reduced by 70% 
without compromising the negative predictive value for individuals samples, reported to be 
80-100% respective of increasing viral load threshold (Smith et al., 2009). Pooled viral 
loads, therefore, offer a solution to expense aspects of the disease progression-monitoring 
challenges. 
 
E) Dried blood spots (DBS) 
Conventional viral load tests are performed on plasma, the collection of which requires 
skilled phlebotomists and a means of isolating the plasma from whole blood. Dried blood 
spot (DBS) technology is a point-of-care method of sample collection that simply involves 
spotting a small volume of blood, possibly a finger-prick, onto filter paper and allowing to 
dry overnight, before sending to a centralised routine viral load laboratory for RNA 
extraction and subsequent testing (McNulty et al., 2007; Neogi et al., 2012). DBS use 
displayed clinical sensitivity and diagnostic specificity of 100% for predicting plasma 
HIV-1 viral load of above 1000 copies/ml (Neogi et al., 2012), that reduces with reduction 
in viraemia (Johannessen et al., 2009). Combination with Nucleic Acid Sequence Based 
Amplification (NASBA) viral load testing resulted in 91% and 97% sensitivity and 
specificity respectively for predicting virologic failure (Johannessen et al., 2009). Although 
dry-blood spots also contain proviral DNA (McNulty et al., 2007), this does not affect the 
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quantified result if DBS-modified nucleic acid testing platforms are used, such as NASBA, 
which only amplifies RNA (Johannessen et al., 2009). The advantage of DBS technology 
is it minimises blood sample processing and volume of blood handled by primary 
healthcare workers (McNulty et al., 2007; Johannessen et al., 2009; Neogi et al., 2012) 
making it a safer, simpler and cheaper alternative to venepuncture.  
 
Both the p24 and RT assays are still a challenge in resource-limited settings due to the 
skills required for their complex operation. Point of care platforms and technologies 
improve access to disease progression-monitoring and timely initiation of treatment and 
regimen switching. Still, a number of challenges affect the efficacy of such technologies in 
the resource-limited settings. Lack of stringent adherence to operation instructions can 
generate a high rate of false-negative results (Wolpaw et al., 2010). The importance of 
adhering to the specified time-to-result readout are of particular concern (Wolpaw et al., 
2010), and the importance of this should be well demonstrated as part of training. Point-of 
care technologies are also limited by lower sample capacity than the current gold standard 
tests, and the use of miniaturised sample input volumes can compromise accuracy (Wu and 
Zaman, 2012). The cost per test of point-of-care platforms is generally lower than the 
equivalent gold-standard, permitting short-term cost savings. But often costs of continued 
use, including requirements for additional reagents or biological waste disposal are 
overlooked, which may in the long-term equate to costs of the current centralised platforms 
(Wu and Zaman, 2012). This cost is further expounded when considering that these 
devices often focus on just 1 aspect of disease monitoring (Wu and Zaman, 2012; Myer et 
al., 2013) and multiple devices and consumables or reagents may be required to be stocked 
at primary health-care clinics to diagnose and monitor several conditions (e.g. HIV and 
TB) and various stages of the disease process. Personnel running these tests will need 
sufficient training for all of these devices.  
 
F) Loop Mediated Isothermal Amplification (LAMP) 
LAMP is a novel molecular technique which mediates the amplification of nucleic acids 
isothermally. The LAMP reaction is a favourable option for diagnostic assays due to the 
low cost of the technique. The only equipment required to perform the reaction is a heating 
block or 2, a bench-top centrifuge and pipettes to add the nucleic acid to the LAMP 
reaction mixture. Most targets can be detected within 45 minutes to an hour incubation 
period (Zhang et al., 2010). Due to the ‘all-in-one’ capacity of the reaction, many LAMP 
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assays are being developed for detection of a variety of pathogens including HBV, Rift 
valley fever virus (Le Roux et al., 2009), TB (Boehme et al., 2007), HCV (Reddy et al., 
2010), H1N1 influenza (Ma et al., 2010) and HIV-1 (Curtis et al., 2008; 2009), using both 
DNA and RNA (RT-LAMP) (Soliman and El-Matbouli, 2009; Buates et al., 2010) as 
template. These assays are simple to perform and interpret, making them even more 
advantageous for resource-limited settings (Boehme et al., 2007). While quantitative 
assays are also being developed (Cai et al., 2008) this has not yet been done for HIV-1 and 
the technique is yet to be implemented commercially. 
 
1.2.3. LAMP mechanism 
Similar to PCR, the LAMP reaction takes place by oligonucleotide-primer directed 
addition of deoxyribo-nucleotides to a growing chain of DNA, catalysed using a high-
strand displacement activity polymerase (Notomi et al., 2000). In conventional PCR, heat 
denaturation, between 95°C - 97°C, brings about template and daughter strand 
displacement. This serves to initiate each cycle of PCR, after which oligonucleotide 
primers can bind to the now single-stranded DNA. This step is not required in the LAMP 
reaction as the BSt Polymerase catalysing the reaction displays characteristically high 
strand displacement activity, which is further mediated by the interaction between 2 
distinct pairs of primers, namely outer primers (F3 and B3) and loop-generating inner 
primers (FIP and BIP) (Notomi et al., 2000). The inner primers consist of 2 sequences, 1 
complimentary to the target and 1 which is identical to a sequence further downstream, 
forming a 5’ overhang when the first piece binds  (Fig. 1.3) (Notomi et al., 2000). The 
overhang will subsequently loop back and bind to its complement on the daughter strand 
(Fig. 1.3) (Notomi et al., 2000). As this happens, outer primers, which are much like the 
forward and reverse primers used in PCR, will bind upstream to the inner primers, 
displacing the stem-loop structured, daughter strand (Fig. 1.3) (Notomi et al., 2000). 
Therefore, with no need for heat denaturation at the start of each reaction, LAMP is run at 
a temperature equivalent to the annealing step of PCR and terminated at 85°C within an 
average incubation period of 1 hour.  
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Figure 1.3 Schematic diagram of the mechanism of loop-mediated isothermal amplification 
(Notomi et al., 2000). 1) Initial binding of FIP and F3 primers to the template nucleic acid; 2) 
Strand displacement is achieved by displacement of the partially single-stranded, extended FIP 
primer by extension of the upstream F3 primer hybridised to the same strand; 3) The double-
stranded DNA product following extension of primer F3; 4) The F1c portion of the FIP strand 
loops back due to extension of FIP passed the complement of F1c (F1), to which BIP and B3 is 
able to hybridise and begin a chain reaction; 5) Extension of the BIP primer causes the unravelling 
of the loop formed by FIP in step 4 to form a double-stranded amplification product; 6) Subsequent 
amplification products can consist of loops formed both by FIP and BIP; 7) The single-stranded 
nature of the loops in the amplification products can hybridise to free FIP (or BIP) to permit 
autocycling; 8-10) Continous formation and unravelling of loops as a result of continued primer-
hybridisation and primer extension-induced strand displacement permits amplification of DNA 
with varying multiples of stem-loop regions. 
 
A number of adaptations and applications to LAMP have emerged since its initial 
development by Notomi et al. (2000). A pair of loop primers additional to the original 2 
outer and inner primers was added (Nagamine, Hase and Notomi, 2002). These loop 
primers hybridise to the loops of the LAMP amplicons just between the F1 and F2 regions, 
and will therefore only bind to loops formed from the target sequence (Nagamine et al., 
2002). The main function of these extra primers is to speed up the auto-cycling phase of 
the reaction (Nagamine et al., 2002).  
 
Apart from DNA, LAMP has been adapted for RNA amplification with the addition of a 
robust reverse transcriptase (RT) with the LAMP reaction mixture, allowing for 
simultaneous cDNA synthesis and amplification in a single step (Notomi et al., 2000; 
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Buates et al., 2010; Cardoso et al., 2010). The activity of AMV RT, for example, is optimal 
at temperatures between 50°C and 65°C, which fits in with the LAMP incubation 
temperature range required by BSt Polymerase. 
 
A) Analysis of LAMP amplification 
Magnesium pyrophosphate (Mg2P2O7) produced as a phosphate group is released with 
dNTP incorporation into the growing DNA chain, which reacts with magnesium sulphate 
in the LAMP reaction. As amplification continues, the by-product builds up in a manner 
which changes the turbidity of the reaction mixture (Mori et al., 2004; Yoshikawa et al., 
2004). As a result, a turbidometer can be coupled to an isothermal heating device to 
monitor by-product accumulation in real time (Mori et al., 2001; Le Roux et al., 2009). 
Through this, Mori et al. (2001) established a correlation between the increase in Mg2P2O7-
induced turbidity and accumulation of LAMP-amplified DNA. This suggests that a means 
able to detect the amount of by-product should indirectly reflect the amount of DNA 
produced.  
 
The by-product forms a white precipitate following pulse-centrifugation of the inactivated 
reaction mixture (Le Roux et al., 2009). Mg2P2O7 can further be detected using metal-
chelating dyes such as hydroxy-naphthol blue (HNB) (Zippelius et al., 2000; Goto et al., 
2009; Ma et al., 2010; Hadersdorfer et al. 2011). HNB behaves stably in the LAMP 
reaction mixture, changing it from violet to blue upon interaction with the free magnesium 
ions (Zippelius et al., 2000; Goto et al., 2009; Ma et al., 2010; Hadersdorfer et al. 2011).. It 
has been employed for end-point detection in the LAMP reaction to determine a qualitative 
positive or negative result, as with H1N1 influenza for example (Ma et al., 2010) but this 
has not been applied in the context of HIV. The sensitivity of HNB is comparable to dyes 
that directly detect DNA products, detecting the same number of amplification-positive 
reactions as SYBR Green (Goto et al., 2009). It does not interfere with amplification and 
therefore can be added to the reaction mixture prior to incubation (Goto et al., 2009). This 
limits opportunities for incorrect result interpretation via cross contamination following 
opening the tube post-amplification. Calcein, similar to HNB, might also be used for 
LAMP detection (Liang et al., 2009) however, it increases reaction cost, as it is a 
fluorescent dye that requires a UV light source for result interpretation adding to 
equipment costs and the requirement for further skills or training (Goto et al., 2009). It is 
10 times less sensitive than HNB compared to SYBR Green (Goto et al., 2009).  
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Other more specific detection methods, also used for quantitative PCR have been 
employed, such as addition of SYBR green (Reddy et al., 2010; Zhang et al., 2010), Gel 
Red™ (Nakao et al., 2010) or fluorescent probes (Curtis et al., 2009). SYBR green 
fluoresces when intercalated with double-stranded DNA for which the emitted 
fluorescence can be measured and compared against a set of quantitative standards 
(Skeidsvoll and Ueland, 1995). Probes on the other hand are single-stranded sequences of 
DNA, similar to oligonucleotide primers, attached to a fluorescent tag (Abravaya et al., 
2003). Although the specificity of such technologies is desirable, cost is a major drawback 
with regard to implementing them in a low-cost, point of care assay. SYBR green is an 
expensive dye, as are fluorescent probes and fluorescence-detection apparatus. Further, 
fluorescent materials are photodegradable with stringent storage requirements. Such 
technologies also require added controls against false positive results, pertaining to 
background fluorescence or malfunction of apparatus, so adding to the complexity of such 
a test. 
 
B) LAMP specificity and sensitivity 
The LAMP reaction is very specific as the requirement for 4 to 6 primers targeting 6 to 8 
regions of the same gene makes it nearly impossible to correctly amplify non-template 
nucleic acids (Notomi et al., 2000). Assays developed for detection of viral pathogens have 
proved to be strain-specific (Yoshikawa et al., 2004), since the same virus infecting a 
species different to the target host could not be detected. This is important for HIV viral 
load testing in South Africa, as of the 2 types of HIV, HIV-1 and HIV-2, HIV-1 is most 
prevalent; specifically sub-type C (van Harmelen et al., 1999). It is suggested that 
efficiency of amplification is hindered when using primers designed to regions with lower 
than 90% sequence identity (Zhang et al., 2010). 
 
Sensitivity of LAMP varies from application to application, with some studies reporting 
amplification of as little as 10 copies of the target (Nakao et al., 2010; Reddy et al., 2010) 
or no less than 200 copies (Cai et al., 2008) depending on the detection format (Yoshikawa 
et al., 2004). If needs be, LAMP sensitivity can be adjusted by adjusting the reaction time 
(Yoshikawa et al., 2004; Hadersdorfer et al., 2011). A low sensitivity can be exploited for 
threshold copy number quantification. For example, a LAMP assay with a 100 copy 
detection limit will successfully distinguish between a sample containing 100 copies of the 
target or a sample with more copies, as the 100 copy sample will appear negative. This is 
19 
 
highly useful for an assay for which the clinical decision does not require an absolute 
value, such as that of HIV viral load, whereby virologic failure is defined as anything 
above 1000 copies HIV RNA/ml plasma (Department of Health, 2013). 
 
Amongst the discussed approaches, LAMP seems to be the most promising. Although not 
commercialised, there is evidence that the reaction can be converted to a point of care 
format (Boehme et al., 2007; Bearinger et al., 2011; Njiru, 2012). Further advantages 
essential to the resource limited setting include a same-day turn-around-time and limited 
infrastructure required. Still, an RT-LAMP based viral load assay remains to be developed. 
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1.3 Study aims and objectives 
The aim of this study was to identify or develop a low cost and simple means of assessing 
disease progression in HIV infected individuals, which would have the potential of being 
suited to a resource-limited setting.  
Various clinical markers were investigated in the literature, of which none were deemed 
favourable, either due to the lack of sensitivity or specificity of these markers as predictors 
of disease progression, or due to the complexity of the techniques used to measure them.  
Alternative techniques for measuring the conventional markers, specifically viral load, 
were also reviewed. The most promising of these techniques was a novel nucleic acid 
based RT-LAMP technique. The technique uses cheaper reagents than others and only 
requires a heating block and centrifuge to perform. The simplest diagnostic tests are 
analysed by colorimetric indicators visible to the naked eye, such as the conventional HIV 
antibody tests and urine dipstick tests. RT-LAMP can also be analysed this way when 
combined with the hydroxy-naphthol blue, metal-chelating dye. The kinetics of the RT-
LAMP assay are similar to real-time PCR, whereby a larger amount of template is 
amplified faster than a smaller amount. Added to this is a limited sensitivity, amplifying no 
less than a 100 copies of template in 60 minutes.  
Taking all of these characteristics of the technique into consideration, the RT-LAMP 
technique, combined with the colorimetric HNB dye was chosen as the basis for a low-cost 
viral load assay. The specific aim of this investigation was to test if the RT-LAMP 
technique could be applied semi-quantitatively for HIV-1 viral load monitoring by 
exploiting the reaction between the RT-LAMP by product and HNB so that a colour 
change from violet to blue would be indicative of a clinically relevant detectable viral load, 
such as above 400 copies or 1000 copies of HIV-1 RNA per ml. 
Assay development consisted of optimising HIV RNA template preparation and the 
various components of the RT-LAMP reaction by: 
i) Evaluating various methods  of isolating plasma from whole blood 
ii) RT-LAMP primer design against 2 of the most conserved gene regions of HIV-
1 RNA genome: Integrase and p24 
iii) Determining optimal concentrations of RT-LAMP reagents for highest assay 
efficiency 
iv) Determining the optimal conditions for stable dye interactions 
v) Investigating whether HNB dye can be applied semi-quantitatively 
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vi) Testing the optimised RT-LAMP assay on RNA obtained from HIV-1 infected 
individuals undergoing routine viral load testing by real-time RT PCR. 
 
The methods used to achieve the above objectives included: 
i) Viral RNA extraction from HIV-1 positive whole blood, and 2 control samples: 
the WHO 2
nd
 standard for HIV-1 (sub-type B-spiked plasma) and culture 
supernatant of HIV-1 sub-type C isolate DU179 
ii) In silico primer design 
iii) RT-LAMP 
iv) Qualitative and quantitative agarose gel electrophoresis 
v) Restriction digestion analysis 
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Chapter 2 
2.1 Methods 
RT-LAMP viral load assay development 
Studies have shown that the strongest tool for monitoring progression of HIV disease is 
measurement of viral load (Jurriaans et al., 1994, Mellors et al., 1997). The most direct 
means of measuring viral load is by detecting the virus genetic material using nucleic acid 
based techniques. Reverse-transcription loop-mediated isothermal amplification (RT-
LAMP) is a low-cost, simple, dynamic nucleic acid amplification technique (Notomi et al., 
2000). This technique was therefore selected as the basis of the low-cost, rapid viral load 
assay.  
 
LAMP is a means of isothermal amplification of nucleic acid (Notomi et al., 2000). The 
reaction amplifies RNA when accompanied with a suitable reverse transcriptase (RT), 
termed RT-LAMP (Notomi et al., 2000; Buates et al., 2010; Cardoso et al., 2010). The use 
of RT-LAMP with the aid of hydroxy-naphthol blue dye (HNB) in a viral load detection 
application is a novel approach, both to HIV-1 viral load detection and RT-LAMP. The 
work represented below was performed at the Medical Oncology Research Laboratory at 
the Department of Internal Medicine, Faculty of Health Sciences. Biosafety clearance 
(number IB110502) was obtained for work performed on live HIV-1 virus. Ethics 
clearance (certificate number M10418, Appendix A) was obtained from the Human Ethics 
Research Committee for collection of HIV-infected and non-infected human whole blood 
upon informed consent. 
 
It was necessary to first optimise the assay with the purpose of ensuring that the assay 
distinguishes between detectable and undetectable viral load consistently. This initial 
optimisation phase consisted of designing and testing the LAMP oligonucleotide primers; 
determining concentrations of various reaction components for optimal RT-LAMP 
amplification; extrapolating the minimum duration of the reaction upon which a colour 
change from violet to blue indicates a detectable viral load, at least 1000 copies HIV 
RNA/ml; and applying the optimised reaction conditions to attempt to semi-quantify viral 
load results of 10 South African HIV positive samples.  
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2.1.1 Sample preparation and RNA extraction 
The RT-LAMP viral load assay was developed using 3 sources of live HIV virus being: 
whole blood of infected individuals, WHO 2
nd
 international HIV-1 standard plasma 
(NIBSC) (Appendix B) and HIV-1 culture supernatant isolate DU179, a gift from the Lynn 
Morris virology lab (The Centre for HIV & Sexually Transmitted Infections, NICD, 
Johannesburg). Whole blood was also collected from 5 HIV-negative, healthy volunteers. 
Following informed consent (Certificate no. M10418, Appendix A), whole blood was 
collected in EDTA vacutainer tubes (Becton, Dickinson, New Jersey, USA) from HIV 
positive individuals attending the Themba Lethu clinic at Helen Joseph Hospital, 
Johannesburg, South Africa. WHO standard plasma (NIBSC, Hertfordshire, UK) and HIV-
1 culture supernatant, produced off-site, were obtained for use as controlled sources of live 
virus. Virus culture supernatant is the viral extract obtained from infected cell-culture. 
Generally, lymphocytes are cultured and infected with a single, homogenous isolate of 
HIV-1. With the replication of the virus, progeny are released into the growth medium of 
the lymphocytes. The progeny are then isolated by centrifugation of the culture producing 
an intact, cellular pellet and supernatant consisting of homogenous suspension of progenic 
virions.  
 
Conventional viral load testing is performed on RNA extracted from patient’s plasma. 
Plasma is used because it is a cell-free component of the blood. Also, the proviral DNA 
and viral transcript RNA contained in the cell do not represent the number of replicating 
virions. Thus, by excluding infected cells, this ensures that only the genomic RNA of the 
virus is counted. Although plasma is cell-free, it may contain protein-material and salts 
which interfere with purity and quality of extracted RNA. In order to optimise the process 
of obtaining HIV-1 genomic RNA, several methods of plasma isolation and pre-extraction 
plasma preparation were explored: 
 
A) Plasma isolation 
i) Plasma was isolated from whole blood by centrifugation at 1000xg for 5 
minutes. The clear plasma supernatant was transferred to cryovials (Greiner-Bio) at 
a total volume of up to 3 ml and stored at -20°C by slow-freezing, until required.  
ii) Whole blood collected in EDTA-coated collection tubes (Becton, 
Dickinson, New Jersey, USA) was centrifuged at 12000xg (4000 rpm) for 20 
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minutes then transferred to cryovials (Greiner-Bio) at a volume of up to 3 ml and 
stored at -70°C, until required. 
 
iii) Whole blood collected in EDTA-coated collection tubes (up to 5 ml) or 
previously isolated plasma (1 ml) was transferred to a serum separator tube (SST) 
(Becton, Dickinson, New Jersey, USA) and centrifuged at 1100xg for 15 minutes. 
Note that serum separator tubes are blood collection tubes which contain a gel 
substance that liquefies during centrifugation allowing cells and proteins to sink 
below the gel, while the serum remains above it. When centrifugation is stopped, 
the gel solidifies, creating a barrier between serum and blood cells. The supernatant 
above the gel barrier was transferred to cryovials (Greiner-Bio) in 1 ml aliquots and 
stored at -70°C until required. 
 
B) Pre-extraction preparation 
i) Plasma  
It has been suggested that viral concentration improves RNA yield and quality. The 
Qiagen RNA extraction (Qiagen, Hamburg, Germany) procedure which was used 
requires 140-200 µl of plasma as starting material. For conventional viral load 
testing, the starting volume of plasma is 1 ml. Therefore, in order to keep to 
conventions, viral particles occurring in 1 ml of plasma were concentrated via 
centrifugation to a volume appropriate for use in the Qiagen extraction procedure. 
Concentration was performed by thawing plasma on ice, vortexing and transferring 
1 ml into 1.5 ml Eppendorf tubes which were centrifuged at 23000xg for 60 
minutes at 4°C. The resulting pellet was resuspended in plasma (200 µl) if obtained 
from plasma, or phosphate buffered saline (PBS) (Sigma-Aldrich, St Louis, USA) 
(200 µl) (Appendix B) if obtained from culture supernatant and kept on ice before 
proceeding with the Qiagen Viral RNA extraction procedure. 
 
ii) HIV-1 isolate DU179 culture supernatant  
Culture supernatant was stored at -70°C in 1 ml aliquots until required, to eliminate 
negative effects of repeated freeze-thaw cycles. Culture supernatant (1ml) was 
thawed on ice and subjected to viral particle concentration as described in (B.i) 
above and the pellet resuspended in PBS (200 µl) (Appendix B) before proceeding 
with the extraction.  
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C) RNA extraction 
RNA was extracted from all of the above preparations using a silica-column based method 
specific for viral nucleic acid extraction from cell-free fluids (Qiagen). Traditionally, a 
phenol-chloroform method is employed using various buffers that allow isolation of the 
RNA from protein, polysaccharides and DNA (Blackburn and Gait, 1996). A guanidine 
thiocyanate (GuTc) buffer, also containing sodium salt (PrimerDigital), causes the 
precipitation of polysaccharides and DNA, which is pelleted following centrifugation, and 
the RNA-containing supernatant is then removed for further processing (Blackburn and 
Gait, 1996). GuTc is a chaotropic agent which assists the RNA extraction process in 2 
ways, by chaotropic disruption of nuclease enzymes which destroy nucleic acid; and by 
disrupting the protein structures of the viral particles (Blackburn and Gait, 1996). The 
supernatant is next treated with phenol repeatedly, which allows for isolation of the RNA 
from proteins by separation into visible phases (PrimerDigital). The phenol phase contains 
the proteins, while aqueous phase, containing nucleic acids, can be removed from the 
solution and washed with chloroform-isoamyl alcohol (Blackburn and Gait, 1996). The 
chloroform removes residual phenol while the alcohol (ethanol is also used), precipitates 
the RNA.  
 
Similarly, the Qiagen procedure consists of lysing the viral particles by incubation of the 
cell-free fluid in a lysis buffer containing GuTc (buffer AVL), except RNA isolation is 
simplified as RNA can bind to a silica-membrane under high salt conditions. Ethanol is 
added to the lysate to adjust the pH for nucleic acid binding to the silica column. 
Polysaccharides, proteins and other debris present in the lysate are pelleted into a 
collection tube attached to the silica column during centrifugation. Instead of requiring 
transfer of the supernatant, the RNA is retained with the silica column for further 
processing, eliminating the need for repeated phase separation. The column is then washed 
with 2 wash buffers (AW1 and AW2), the first containing Guanidine chloride and ethanol, 
repeatedly to remove residual lysate and buffer, to ensure that the extract does not contain 
contaminating proteins or chemicals that would compromise the quality of the RNA. The 
guanidine chloride in this step causes chaotropic disruption of contaminants and nucleases. 
In the second wash step, the ethanol concentration is changed to prepare the RNA extract 
for elution from the column. Lastly, the extract is eluted from the column by incubating the 
silica membrane with nuclease-free dH2O or a low salt buffer, which is unfavourable for 
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binding to silica, and aids elution of the RNA, followed by high-speed centrifugation to 
release the extract from the column. 
 
i) Qiagen Viral RNA extraction 
The extraction was performed as per Qiagen’s instructions. Starting material (200 µl), of 
either plasma or virus resuspended in PBS, was combined with buffer AVL™ (560 µl) and 
carrier RNA (5.6 µl) provided with the kit (Appendix B), pulse-vortexed for 15 seconds 
and incubated at ambient temperature for 10 minutes. RNA occurring in very small 
amounts is susceptible to degradation. The addition of carrier RNA increases the 
concentration of RNA on the column and in the eluate, providing stability for low yields of 
RNA. Following lysis, 100% molecular grade ethanol (560 µl) (Sigma-Aldrich, St Louis, 
USA) was added and pulse-vortexed for 15 seconds. Thereafter, the lysate (630 µl) was 
applied to the provided silica column and centrifuged at 6000xg (8000 rpm) for 1 minute. 
This was repeated on the same column for the remainder of the lysate, followed by 
washing the column of residual buffer and plasma in 2 steps with buffers AW1™ (500 µl) 
and AW2™ (500 µl). Before elution it is recommended to dry the column of residual 
buffer by an added centrifugation step at 8780xg (14000 rpm) for 1 minute. It was tested 
whether inclusion or exclusion of this additional step optimised yield and quality of the 
RNA extract. Although inclusion of the step is recommended by the manufacturer, it was 
found that exclusion lead to better yield and quality based on Nanodrop™ 
Spectrophotometry (see below). RNA was eluted by on-column incubation of nuclease-
free dH2O (30 µl) (Thermo Scientific, Massachusetts, USA) for 5 minutes at ambient 
temperature, before centrifugation at 6000xg (8000 rpm) for 1 minute. RNA was quantified 
and qualified using NanoDrop™ (Thermo Scientific, Massachusetts, USA). The 
Nanodrop™ is a spectrophotometer that measures nucleic acid and protein concentration in 
a sample volume of 1-2 µl. The RNA extract (2 µl) was applied to the Nanodrop™ 
platform and optical density was measured at an absorbance wavelength of 260 nm (A260) 
to determine concentration of RNA in ng/µl whereby 1 optical density (OD) unit is 
equivalent to 40 µg RNA. The readings were normalised against the same nuclease-free 
dH2O used in the RNA elution step, known as a blank.  The quality of the extract was 
determined by the ratio of OD at A260 to that of 230 nm (A230) and 280 nm (A280). The 
A260/230 ratio determines contamination with chaotropic salts and ethanol which may 
have inhibitory effects in downstream enzymatic reactions, while the A260/A280 ratio 
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indicates the presence of contaminating proteins. The optimal ranges for the A260/A230 
and A260/280 are 1.7-2.0 and 1.8-2.0 respectively.  
 
2.1.2 RT-LAMP primer design 
This was the first step in the development of the assay and consisted of in silico primer 
sequence selection targeting relevant gene regions and in vitro testing of the primers for 
amplification efficiency and specificity. 
 
A) In silico sequence selection 
The RT-LAMP amplification is brought about by the action of loop-forming primers, 
named forward inner (FIP) and back inner (BIP), producing single-stranded regions within 
the DNA amplicons that can be easily displaced and separated without the need for heat-
denaturation and therefore multiple temperatures within a single amplification cycle. This 
helps to make this technique take-place isothermally. These loop-forming primers are 
around 40 nucleotides long and designed from 2 neighbouring, but complimentary regions 
within the desired target gene sequence. Oligomers of this size are prone to contamination 
as well as self-complementarity, also known as primer self-annealing. When self-annealing 
occurs, off-target, false positive amplification takes place and the efficiency of 
amplification of the target is greatly reduced. Further, this technique requires an additional 
2 primer pairs: outer primers (F3 and B3), similar to PCR primer pairs which initiate the 
very first amplification cycle of the LAMP reaction, and loop primers (loopF and loopB). 
Loop primers hybridise to the loop-region of the amplicons to accelerate exponential 
amplification of the products. As these primers can only bind to products formed from the 
first 2 primer pairs, they also aid the specificity of the entire reaction. However, the need 
for a total of 6 oligomers targeting 1 target gene increases the chances of primer-self-
annealing, and in silico prediction tools are required to predict the sequence-dependent 
likelihood of off-target amplification.   
 
Oligonucleotide primers, including published primers and self-designed primers were 
designed for LAMP according to the recommendations of Notomi et al. (2000) for the 
outer and inner primer sets and Nagamine et al. (2002) for the Loop primer pair. Four 
primer sets were assessed including, integrase-1, -2, and integrase-DU179 and published 
primers targeting p24 (Curtis et al., 2009) (Appendix C). Once primer sequences were 
obtained and synthesised, each set was applied to the RT-LAMP reaction and tested for 
28 
 
specificity to HIV-1 using restriction digestion analysis. Each of the primer sets are 
discussed below. 
 
Integrase-1: The integrase-1 primer set was designed against the integrase gene region of 
the Pol gene of South African HIV-1 isolate 05ZAJF04 (GenBank accession no. 
GQ872538.1). Primers iF3 and iB3 were obtained using NCBI primer blast  (Ye et al., 
2012), while the inner (iFIP and iBIP) and loop primers (iLoopF and iLoopB) were self-
selected according to the guidelines of Notomi et al. (2000) and Nagamine et al. (2002).  
 
Integrase-2: The second set of primers targeting the integrase region was designed against 
a sub-type C reference sequence (GenBank accession no. AF286227) listed in the Los 
Alamos reference sequence database. The total of 6 oligomer sequences, including i2F3, 
i2B3, i2FIP, i2BIP, i2Loop F and i2Loop B, were selected by assessing for self-
hybridisation, using IDT Oligo Analyser (Integrated DNA Technologies, Inc., 2013) and 
North Western Edu Oligo Calc web-based prediction tools (Kibbe, 2007). 
 
Integrase-DU179: The fourth set of primers was designed against the sequence of isolate 
DU179 (GenBank accession no. AY043174.1.), for specific RT-LAMP testing on the 
DU179 culture supernatant sample. For this, LAMP primer design software, Primer 
Explorer 3 (Fujitsu Ltd.) was used. Primer Explorer 3 generated a list of possible primer 
sets for the outer (DF3 and DB3) and inner primer pairs (DFIP and DBIP). A single set of 
primers was selected by a process of elimination by assessing each set for self- and cross-
hybridisation using the jPCR software (Kalender, Lee and Schulman, 2011). Loop primers, 
DloopF and DloopB, were self-selected for the chosen set of primers according to the 
guidelines of Nagamine et al. (2002) and the final set of 6 primers was assessed using 
jPCR (Kalender et al., 2011) and for specificity to HIV-1 across the nucleotide database of 
the nucleotide BLAST alignment tool (Altschul et al., 1990).  
 
P24 by Curtis et al. (2008): The exact pF3, pB3, pFIP, pBIP, pLoopF and pLoopB primer 
sequences published by Curtis et al. (2008), targeting the p24 gene region of the Gag gene 
of a sub-type B sequence, for LAMP detection of HIV-1, were tested for reproducibility in 
the RT-LAMP viral load assay. 
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B) LAMP and RT-LAMP reaction parameters 
Reaction conditions for successful RT-LAMP amplification are well described in the 
literature (Notomi et al., 2000; Curtis et al., 2008; Goto et al., 2009). Generally, the LAMP 
reaction mixture was made to contain final concentrations of hydroxy-naphthol blue 
(HNB) (0.12 mM) (SAS Chemical, Mumbai, India), BSt DNA polymerase (8 U) (Lucigen, 
Middleton, USA), MgSO4 (6 - 10mM) (Sigma-Aldrich, St Louis, USA), deoxyribo-
nucleotide triphosphates (dNTP) (1 mM) (Thermo Scientific, Massachusetts, USA), 
Thermopol reaction buffer (1X) (Lucigen, Middleton, USA) (Appendix B), betaine (0.4 – 
1M) (Sigma-Aldrich, St Louis, USA), primer pairs F3 and B3 (0.2 µM); FIP and BIP (1.6 
µM); Loop F and Loop B (0.8 µM) and made up to a final volume of 25 µl with sterile, 
nuclease-free distilled water (Thermo Scientific, Massachusetts, USA). Reaction 
conditions for RT-LAMP are also well characterised in the literature (Notomi et al., 2000; 
Curtis et al., 2008, 2009; Buates et al., 2010), and are the same as the above with inclusion 
of 2.5U - 10U Thermoscript reverse transcriptase (ThermoscriptRT) (Invitrogen, Life 
Technologies, Carlsbad, USA) or AMV reverse transcriptase (AMV RT) (Promega, 
Madison, USA) and RNA template as opposed to DNA template is added. Acquisition of 
RNA template is described above (section 2.1.1). In some cases DNA template was added 
in the form of integrase clone sequences FV20 and FV23 donated by the HIV Pathogenesis 
Lab (Department of Molecular Medicine, Wits Med School). The reaction mixture was 
incubated in a BioRad MJ Mini Thermocycler (BioRad, Hercules, USA) following the 
parameters outlined in Table 2.1. LAMP and RT-LAMP does not require the use of a 
thermocycler. Here, the use of a thermocycler instead of heating block was for the 
convenience of automation of a single temperature change from incubation temperature to 
inactivation temperature, as well as for the use of a temperature gradient, which aided in 
reaction temperature optimisation. 
 
 
Table 2.1 Programme for performing LAMP and RT-LAMP on a thermocycler. The BioRad MJ 
Mini Thermocycler was used to perform the reactions.  
LAMP and RT-LAMP 
programme 
Temperature (°C) Time 
Incubation 58-65 depending on primer 
set 
1 or 2 hours 
Inactivation 85 5 minutes 
Hold 4 indefinitely 
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C) Post RT-LAMP analysis 
RT-LAMP amplification detection is simplified by the presence of the reaction by-product, 
magnesium pyrophosphate (Mg2P2O7), which presents as turbidity, a white precipitate or 
reactant with metal-chelating dyes. Here, precipitation of Mg2P2O7 and reaction with HNB 
dye were used to observe reactions for amplification confirmed by the presence of DNA 
stem-loop products forming a ladder-like agarose gel electrophoresis pattern. The factors 
relating to post RT-LAMP analysis are considered below. 
 
i) Magnesium pyrophosphate precipitation 
As dNTPs are incorporated into the growing chains of LAMP amplicons, phosphate ions 
are released which react with MgSO4 to form Mg2P2O7. Reactions positive for nucleic acid 
amplification become turbid due to the formation of Mg2P2O7 (Mori et al., 2001). To 
precipitate the Mg2P2O7, as an indicator of a positive reaction, following inactivation of the 
RT-LAMP reaction at 85°C, reaction tubes were centrifuged at 20000xg (7000-8000 rpm) 
for approximately 5 seconds, 3 times. The precipitate was observed as a small, white 
sphere at the bottom of the tube. 
 
ii) Hydroxy-naphthol blue colour change 
Hydroxy-naphthol blue dye, violet in colour, is conventionally used as a metal titration 
indicator, due to the change from violet to blue with increasing presence of metal ions. It is 
used in the LAMP reaction to detect the change in Mg
2+
 ions that takes place with the 
accumulation of Mg2P2O7 as nucleic acid is amplified. The colour was recorded 
photographically using the Samsung GT-S5233A camera phone with 2048 x 1536 pixels 
resolution at time 0 of incubation and following inactivation of the reaction. 
 
iii) Agarose gel electrophoresis  
RT-LAMP produces amplicons containing various multiples of stem and loop DNA 
structures and therefore occurs as a ladder-like banding pattern when analysed by agarose 
gel electrophoresis. RT-LAMP reaction mixture (5 µl) combined with 6X agarose gel 
loading buffer (1 µl) (Thermo Scientific, Massachusetts, USA) was loaded onto a 2% TAE 
agarose gel (Appendix B). DNA was visualised with the aid of GR Green DNA dye (Clare 
Chemical, Colorado, USA) either added to the liquid gel or to the loading buffer. 
Electrophoresis was performed at 60-110V at a constant current for 90 – 120 minutes, in 
1X TAE buffer (Appendix B). The subsequent gel was viewed and photographed using the 
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ChemiDoc XRS UV transilluminator (BioRad, Hercules, USA) and QuantityOne gel 
imaging software supplied with the equipment.  
 
iv) Restriction digestion 
The specificity of the reactions was determined by restriction digestion analysis of the RT-
LAMP products. Restriction endonucleases cleave DNA at a recognition sequence specific 
to each endonuclease. By selecting an endonuclease with a restriction recognition site 
occurring in the expected sequence of DNA, one can assess if that DNA is present in a 
sample following cleavage to sizes pertaining to the correct recognition sequence, and 
which can be analysed by agarose gel electrophoresis.  
 
The target sequence, spanning the region between F2 and B2, was entered into NEB Cutter 
v.2.0 Restriction mapping tool (NEB), which identified a BSeXI restriction recognition 
site. Prior to digestion with BSeXI, the LAMP product was purified from the reaction 
mixture using the GeneJet Purification kit (Thermo Scientific, Massachusetts, USA), 
according to the manufacturer’s protocol (Appendix E). The GeneJet purification 
procedure is a silica-affinity column procedure similar to that of the viral RNA extraction. 
Initially, the LAMP reaction mixture was added to a binding buffer which contains GuTc 
and potassium acetate. The GuTc causes chaotropic disruption of the enzymes and reagents 
(Blackburn and Gait, 1996) in the LAMP reaction, while the potassium acetate provides a 
high-salt environment that favours binding of the LAMP-amplified DNA to the silica 
membrane of the silica affinity column. Centrifugal forces cause the disrupted LAMP 
reagents to be drawn through the column in solution, collected in a collection tube which 
was discarded, while the DNA remained bound. This was followed by washing with a 
wash buffer, also containing GuTc, ensuring any remaining LAMP reagents are disrupted 
and discarded, along with ethanol which maintains a favourable pH for DNA binding to 
the column. The column was subsequently dried by centrifugal forces, to remove residual 
wash buffer. The column was then incubated with Tris-HCl, a low salt buffer, which 
favours release of the DNA from the silica membrane and promotes DNA longevity during 
storage. The DNA was then drawn through the column in solution by centrifugal force into 
a collection tube for storage. 
 
Purified DNA was eluted into Tris-HCl (10 mM) (Thermo Scientific, Massachusetts, USA) 
at a volume equivalent to the starting volume. The DNA (0.5 µg) was then added to a 
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digestion reaction mixture containing 3U BSeXI (Thermo Scientific, Massachusetts, USA), 
1X buffer BSeXI (Appendix B) and made up to 20 µl with nuclease-free water (Thermo 
Scientific, Massachusetts, USA). The mixture was incubated at 65°C for approximately 4 
hours and inactivated at 80°C for 20 minutes. The digestion products were analysed by 
agarose gel electrophoresis as described above, using TBE buffer instead of TAE 
(Appendix B). Generally, TAE is better for resolution of DNA larger than 1kbp while TBE 
is preferred for DNA smaller than 1 Kbp. Prior to addition of gel loading dye, digestion 
products were heated at 65°C in the presence of 1% SDS for 10 minutes as recommended 
by Thermo Scientific to dissociate any residual enzyme-DNA complexes which will affect 
gel migration of the digestion product.  
 
2.1.3  RT-LAMP HIV-1 viral load assay optimisation 
The optimisation of the assay requires determining the optimal reaction conditions for 
consistent nucleic acid amplification efficiency, the optimal temperature of incubation, 
primer design and determining the time-to-positive (TTP). This is done so that the 
proposed viral load assay performs consistently with respect to external variables for 
example template RNA quality, patient sample quality and operator-induced variability. 
The key reagents optimized here were MgSO4 and AMV RT. 
 
A) MgSO4 concentration 
Mg
2+
 ions are required for stabilisation of enzymatic reactions. In a PCR reaction, the Mg
2+
 
concentration impacts the specificity of primer binding as well as amplification efficiency. 
Similarly, in a LAMP reaction, the amount of MgSO4 affects the efficiency of BSt DNA 
polymerase activity, interaction with the dNTPs and primers, and also the formation of the 
magnesium pyrophosphate by-product, the HNB-induced colour change and reverse 
transcription (Goto et al., 2009). The effect of different concentrations of MgSO4 (0 mM, 5 
mM, 6 mM, 7mM, 8mM, 8.5 mM, 9 mM, 10 mM and 12 mM respectively) in the RT-
LAMP reaction were tested for effect on amplification efficiency as well as hydroxy-
naphthol blue dye interaction and reaction colour development.   
 
B) AMV reverse transcriptase: AMV RT activity is stabilised by free Mg2+ions, and 
therefore affects HNB dye interaction and reaction colour development. Therefore, the 
minimum amount of AMV RT at which cDNA synthesis occurred without causing 
premature colour change from violet to sky-blue had to be determined. Upper and lower 
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limits of AMV RT, at 10 U and 2 U respectively, were compared for effect on the RT-
LAMP reaction colour. 
 
C) Gradient LAMP and Gradient RT-LAMP: LAMP and RT LAMP is generally 
incubated at 60°-64°C for an hour and inactivated at 80°C-85°C for 5 minutes as suggested 
in the literature. Some suggest an additional primer-template denaturation step at 95°C for 
5 minutes before addition to the reaction mixture (Notomi et al., 2000). Optimum reaction 
temperature however depends on the specific primer design and characteristics of the 
template RNA or DNA. For this purpose, LAMP was subjected to a number of 
temperatures in a single run, known as a gradient LAMP. This was accomplished using the 
BioRad MJ Mini Thermocycler whereby each row of the thermocycler is heated to a 
different temperature within a specified range. For this purpose, template positive and 
template negative LAMP reaction mixtures were incubated at 55°C - 65°C separately, 
followed by inactivation at 85°C using the same thermocycler. The purpose of assessing 
each temperature simultaneously was to keep reaction setup and performance of equipment 
uniform to ensure that any differences observed in reaction efficiency could be attributed 
to a temperature change alone. 
 
2.1.4 Testing the semi-quantitative capacity of hydroxy-naphthol blue dye detection 
Quantification of the amount of template occurring at the start of a nucleic acid 
amplification reaction can be performed by determining how early the exponential phase of 
amplification is reached. This is the principal behind quantitative real-time PCR, whereby 
a higher amount of template or higher viral copy number will amplify faster than a lower 
amount of template or lower viral copy number. By measuring fluorescent beacons 
released during amplification, the reaction is monitored in real time to determine the exact 
point at which an amplification threshold is reached; and then compared to a standard 
curve to determine an absolute template copy number.  Similarly, the turbidity in a LAMP 
reaction, produced by Mg2P2O7, can be measured in real time and compared to reference 
values as the production of Mg2P2O7 is proportional to the accumulation of LAMP product 
during the LAMP reaction (Mori et al., 2004). It was therefore assessed whether the HNB 
induced colour-change was sensitive enough to detect the rate of accumulation of Mg2P2O7 
relevant to different template concentrations or copy numbers. This was performed by the 
use of a single-self-priming LAMP primer at increasing concentrations in a LAMP 
reaction. This was based on the rationale that the self-priming primer, identified while 
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screening the above-mentioned primer sets (section 2.1.2.A), amplifies itself and therefore 
can be used as template DNA with the added benefit that the primer solution is 
homogenous and therefore the amount of primer solution added is proportional to the 
number of primer copies.  The LAMP reaction consisted of BSt Polymerase (8 U) 
(Lucigen, Middleton, USA), MgSO4 (6-7 mM)(Sigma-Aldrich, St Louis, USA), Betaine 
(0.4 M) (Sigma-Aldrich, St Louis, USA), HNB (0.12 mM)(SAS Chemical, Mumbai, 
India), Thermopol Reaction buffer (1X)(Lucigen, Middleton, USA), dNTPs (1 mM) 
(Thermo Scientific, Massachusetts, USA) and modified by the inclusion of a self-annealing 
lamp inner primer, i2FIP at concentrations of 0 µM, 1.6 µM, 3.6 µM and 16 µM, made up 
to 25 µl in nuclease-free dH2O (Thermo Scientific, Massachusetts, USA). The remaining 
five primers required in a regular LAMP reaction as well as template HIV DNA were 
excluded for control purposes. The reaction was performed in duplicate, incubated at 60°C 
for 5 minutes and 60 minutes respectively, and inactivated at 85°C for 5 minutes. The 
reaction colour as well as presence or absence of a Mg2P2O7 precipitate was recorded at the 
start of the reaction, after 5 minutes to record if heating the solution produces a colour 
change and again after 60 minutes of incubation to observe the end point reaction colour, 
following nucleic acid amplification. The amount of starting concentration of primer was 
compared to the amount of accumulated product analysed by agarose gel electrophoresis to 
confirm the effect of template concentration on the rate of product accumulation after 60 
minutes. This was done using a loading dye sensitive to the amount of DNA present, 
compared to a set of standards. For this, 1 µl of Massruler™ loading dye (Thermo 
Scientific, Massachusetts, USA) was combined with 5 µl LAMP reaction product or 5 µl 
Massruler™ ladder (Thermo Scientific, Massachusetts, USA), and loaded onto a 1% TAE 
gel stained with GR Green gel stain. The gel was imaged as described previously.  
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Chapter 3 
Results 
The experimental results of the development of the HIV-1 viral load RT-LAMP assay are 
presented here. This work includes optimisation of RNA extractions, the design and 
screening of four RT-LAMP primer sets, the semi-quantitative performance of the 
hydroxy-naphthol blue dye, followed by performance of the assay on the viral isolate 
DU179.  
 
3.1 Acquisition of nucleic acid template for development of the RT-LAMP viral load 
assay 
3.1.1 Sample collection 
Nucleic acid-based viral load testing conventionally measures copies of viral RNA per ml 
of plasma as it is an indication of the number of virus particles circulating in the blood of 
an infected individual. RT-LAMP is also a nucleic-acid based technique. Therefore, HIV-1 
RNA was required as the nucleic acid template for the accurate development of the RT-
LAMP based viral load assay. In keeping with conventional viral load test procedures, the 
RNA needed to be extracted from plasma isolated from the whole blood of HIV infected 
individuals. For this study, 27 HIV infected and 5 HIV negative whole blood samples were 
collected. The plasma was isolated upon collection and stored for subsequent RNA 
extraction. WHO 2
nd
 international HIV-1 Standard plasma  and HIV-1 subtype C culture 
supernatant  DU179 were obtained as positive controls.  
 
3.1.2 Sample preparation for RNA extraction 
Purity of the isolated plasma affects the downstream extraction and subsequent 
applications of the extracted RNA. The basic procedure of isolation of plasma from whole 
blood by centrifugation was modified in a number of ways to identify the procedure which 
gave the best quality RNA. Modifications were compared for the same sample where 
sufficient sample volume was available. Where this was not possible, modifications were 
tested across multiple samples. Following extraction of the RNA using the Qiagen viral 
RNA kit (Qiagen, Hamburg, Germany), the quantity and quality of the RNA was 
determined by Nanodrop™ spectrophotometry (Thermo Scientific, Massachusetts, USA). 
Conventionally, RNA and DNA are measured spectrophotometrically by absorbance at 
260 nm (A260), protein is measured at 280 nm (A280) and contaminants such as 
chaotropic salts and ethanol are measured at 230 nm (A230). Therefore, pure quality RNA 
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displays A260/280 and A260/230 ratios of above 1.8, ideally around 2.0. Plasma samples 
stored at -20°C, 8 in total, were not suitable for successful RNA extraction as indicated by 
the low yield and poor quality of the RNA extracted (Table 3.1). Though the 20 000 copy 
dilution of HIV-1 standard was of a good quality, the yield appeared unexpectedly low 
(Table 3.1). Similarly, no correlation was observed between yield and viral copy number 
across the range of dilutions of the HIV-1 standard (Table 3.1). Changing storage of 2 
samples from -20°C to -70°C did not improve the quality of the extracts (Table 3.1). 
However, subsequently collected samples stored at -70°C at first point of use provided 
RNA of an improved yield and quality than those stored at -20°C (Table 3.1). 
 
Table 3.1 Concentration of RNA extracted from plasma showing the effect of plasma storage 
temperature on quantity and quality of RNA extracted using the Qiagen Viral RNA mini kit. 
 C (ng/µl) A260/A230 A260/A280 
Sample I.D. -20°C -70°C -20°C -70°C -20°C -70°C 
WHO STD 30.7 113.6 1.83 1.6 3.2 2.9 
H1 3.9 82.03 0.17 0.36 8.68 1.34 
N1 3.1 - 0.04 - -7.1 - 
WHO STD 40 29.7 - 0.12 - 3.2 - 
WHO STD 400 39.9 - 1.02 - 3.3 - 
WHO STD 1000 41.0 - 0.51 - 3.1 - 
WHO STD 5000 35.0 - 0.68 - 3.4 - 
WHO STD10000 37.9 - 0.90 - 3.0 - 
H4 - 158.7 - 2.27 - 3.4 
H10 - 155.2 - 2.40 - 3.4 
H: HIV-infected plasma; N: HIV Negative plasma; WHO STD: dilution of WHO HIV-1 2
nd
 
standard plasma; C: concentration of RNA; A: absorbance in nm. Favourable and unfavourable 
results indicated in bold and grey respectively. A favourable extract had yield ˃ 80 ng and 
A260/230 of 1.7-3.0.  
 
The process of viral particle concentration was adopted as a standard procedure based on 
the rationale that retaining as many of the viral particles from 1 ml of plasma, as opposed 
to 140 µl of plasma, would be a more accurate representation of the number of RNA copies 
per ml. Centrifugal concentration was a means of adapting the ideal 1ml sample volume to 
the Qiagen procedure requiring ideally 140 µl.  
 
The manufacturers of the Qiagen viral RNA extraction kit recommend an optional step of 
drying the silica column prior to the elution procedure. It was assessed here whether the 
inclusion or exclusion of this step contributed to the quality and quantity of the extract. No 
difference was found between inclusion and exclusion of this step (Table 3.2). 
 
37 
 
 
Table 3.2 Concentration of RNA extracted from plasma and culture supernatant showing the effect 
of inclusion (INCL) and exclusion (EXCL) of the dry-column step recommended in the Qiagen 
viral RNA extraction protocol on purity and quantity of RNA subsequently extracted using the 
Qiagen Viral RNA mini kit. 
 C (ng/µl) A260/A230 A260/A280 
Sample I.D. INCL EXCL INCL EXCL INCL EXCL 
H18 113.6 115.3 2.86 1.80 3.3 3.5 
H15 133.9 115.6 2.23 0.83 3.29 3.53 
H6 50.75 - 2.59 - 4.0 - 
H2 144.1 - 2.89 - 3.5 - 
H3 97 - 2.98 - 3.4 - 
H5 70.01 - 1.43 - 3.3 - 
H10 37.03 - 1.34 - 3.6 - 
H7 35.5 - 1.55 - 3.3 - 
H19 - 55.7 - 0.53 - 3.81 
H20 - 147.44 - 0.58 - 3.27 
DU179  - 124.1 - 2.64 - 3.28 
Plasma stored at -70°C prior to centrifugal concentration. H: HIV-infected plasma; N: HIV 
negative plasma; C: concentration of RNA; A: absorbance in nm; DU179: RNA extracted from 
culture supernatant instead of patient plasma. Favourable and unfavourable results indicated in bold 
and grey respectively. A favourable extract had yield ˃ 80 ng and A260/230 of 1.7-3.0. 
 
Plasma, though free of cells, contains various enzymes and other proteins that may affect 
the extraction process. The use of serum separator tubes (SST) was tested as a means of 
pre-cleaning plasma prior to viral particle concentration. In almost all cases, the use of SST 
improved the purity of the resulting RNA compared to the same samples processed without 
these tubes (Table 3.3). 
 
Through the above performed tests and modifications it was established that the optimal 
procedure for extracting RNA from plasma necessitated SST separation of whole blood, 
followed by high speed centrifugation of 1 ml of isolated plasma. The viral pellet should 
then be resuspended in 200 µl PBS as starting material for the Qiagen Viral RNA mini 
procedure and then processed according to the manufacturer’s protocol, but with exclusion 
of the optional step of drying out the column prior to elution. All plasma and RNA should 
be stored at -70°C. 
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Table 3.3 Concentration of RNA extracted from plasma showing the effect of passing whole blood 
or plasma through serum separator tubes (SST) prior to performing centrifugal concentration on 
purity and quantity of RNA subsequently extracted using the Qiagen Viral RNA mini kit excluding 
the dry-column step. 
 C (ng/µl) A260/A230 A260/A280 
Sample I.D. SST no SST SST No SST SST No SST 
H12 25.7 120.07 0.12 0.6 3.45 3.13 
H16 83.5 74.4 2.17 0.16 3.2 3.6 
H17  113.7 77.0 2.59 0.17 3.2 3.8 
H18  89.46 115.3 1.79 1.80 3.3 3.5 
N4
 
92.5 47.0 1.71 0.60 3.4 3.5 
H13  150.5 - 1.97 - 3.3 - 
H14  135.1 - 0.57 - 3.45 - 
H: HIV-infected sample; N: HIV negative sample; C: concentration of RNA; A: absorbance in nm. 
Favourable and unfavourable results indicated in bold and grey respectively. A favourable extract 
had yield ˃ 80 ng and A260/230 of 1.7-3.0. 
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3.2. RT-LAMP HIV-1 viral load assay primer design 
The unique primer design of RT-LAMP allows the technique to amplify nucleic acid 
isothermally. Six primers are required across 4 regions of the gene targeted for 
amplification. Four of the 6, being the 2 outer primers (F3 and B3) and 2 loop primers 
(Loop F and Loop B) are similar in length to PCR primers. The remaining 2 inner primers 
(FIP and BIP) each span up to 40 nucleotides in length, each corresponding to 2 adjacent 
regions within the target gene and produce the loops in the repeated stem-loop 
amplification products. For the viral load assay, RT-LAMP primers were designed against 
2 target gene regions of HIV-1, p24 and integrase, respectively. These gene regions are 
targeted by commercial real-time RT-PCR viral load assay kits (Abravaya et al., 2003; 
Schumacher et al., 2007). A total of 4 sets of the 6 RT-LAMP primers were designed and 
assessed for suitability for the RT-LAMP HIV-1 assay, 1 targeting p24 and the other 3 
targeting integrase. Primer screening involved performing RT-LAMP with each primer set 
in the presence of patient-obtained HIV-1 template and negative controls (no RT and no-
template controls), and where available, positive controls: WHO standard RNA, DU179 
culture supernatant RNA and cloned integrase DNA. Amplification products were assessed 
for specificity to HIV-1 by restriction digestion analysis.  
 
3.2.1 p24 primer set 
Primers targeting the p24 gene region of the HIV-1 Gag gene, previously designed for an 
RT-LAMP diagnostic assay (Curtis, Rudolph and Owen et al., 2009), were tested to see if 
the published results could be replicated for use in the viral load assay. RT-LAMP was 
performed across a range of incubation temperatures from 58°C to 64°C (Fig. 3.1). 
Although Curtis, Rudolph and Owen (2008) established an optimal temperature for these 
primers, the reaction conditions differed as they did not use the HNB detection method. 
The temperature range applied was ascertained from LAMP literature and recommended 
conditions for BSt Polymerase activity. RNA extracted from patient plasma was applied as 
template, so as to simulate conventional viral load testing. A patient initiating treatment 
was selected as it was expected that such a patient would have a detectable viral load 
although this was not confirmed as viral load testing was unavailable as viral load is not 
done at baseline of treatment initiation according to the South African ART treatment 
guidelines (Department of Health, 2013). 
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Figure 3.1 Gradient RT-LAMP performed on p24-1 primer set to test primer performance when 
RT-LAMP is carried out for 60 minutes at 58°C (lanes 1-3); 60.4°C (lanes 4-6); 62.8°C (lanes 7-9); 
64°C (lanes 10-12). RT-LAMP was performed on RNA (82 ng) obtained from HIV seropositive 
patient H1 initiating treatment (lanes 1,2,4,5,7,8,10 and 11); Controls included no RT (lanes 2,5,8 
and 11)and no template controls (lanes 3,6,9 and 12). For the negative controls water replaced RT 
and RNA respectively. MWM: 1Kb GeneRuler™ (bp) (4 µl). 2% Tris-Boric Acid-EDTA agarose 
gel stained with GelRed nucleic acid gel stain. Electrophoresis performed at 60V for 60 minutes. 
Lanes contain 5 µl reaction products combined with 1 µl GelRed loading buffer. 
 
With agarose gel electrophoresis, amplification was observed at all temperatures (Fig. 3.1), 
evident as a ladder-like banding pattern, made up of products as small as 200 bp up to 10 
000 bp sized products containing multiple stems and loops. All the bands were observed to 
be identical including that of the no template controls (Fig. 3.1). This means that the 
observed amplification on the gel represents that of background, off-target amplification 
and not amplification of HIV RNA, indicating that further optimisation was required. 
 
To aid in determining the source of off-target amplification in the negative controls, it was 
tested whether exclusion of certain reagents prevented amplification in no template control 
experiments (Fig. 3.2A). External sources of contamination were ruled out as basis for the 
off-target amplification as exclusion of RT, betaine, HNB dye, reaction buffer and 
nuclease-free water did not prevent off-target amplification (Fig. 3.2A).  
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Figure 3.2 RT-LAMP performed with primer set p24-1 on no template controls to determine 
source of persistent off-target amplification products occurring in reactions primed by the p24-1 
primer set. A) The following reagents were excluded from the RT-LAMP reaction: RT (lane 1), Bst 
polymerase (lane 2), dNTPs (lane 3), Betaine (lane 4), MgSO4 (lane 5), HNB (lane 6), reaction 
buffer (lane 7), water (lane 8). Reaction performed at 63°C for 60 minutes. B) RT-LAMP using 
p24 primers in a no template control using new stocks of BSt Pol, dNTPs and MgSO4, reaction 
performed 63°C for 40 minutes. A) and B) 1.2 % Tris-Boric Acid-EDTA gel stained with GelRed 
nucleic acid gel stain. MWM: 1Kb GeneRuler™ (2 µl). Electrophoresis performed at 97 V for 60 
minutes (A) and 102 V for 60 minutes (B). Lanes contain 5 µl reaction products combined with 1 
µl 6X loading dye. 
 
Here, amplification was only absent when reagents essential to LAMP, such as BSt 
polymerase, deoxy-nucleotide-triphosphates (dNTP) and MgSO4, were excluded (Fig. 
3.2A). This was confirmed by the persistence of off-target amplification with the use of 
new reagent stocks (Fig. 3.2B). Reducing the reaction time from 60 minutes (Fig. 3.2A) to 
40 minutes (Fig. 3.2B), did not prevent off-target amplification. Overall, the primers 
designed by Curtis et al. (2008), were deemed unsuitable for use in the RT-LAMP viral 
load assay due to the presence of off-target amplification which could later lead to false-
positive results in tested samples.  
 
3.2.2 Integrase-1 primer set 
The 2 gene regions targeted by conventional real-time PCR viral load assays are p24 and 
integrase (Abravaya et al., 2003; Schumacher et al., 2007). In keeping with this 
convention, a second set of primers was designed against the integrase region of the Pol 
gene (Fig. 3.3). RT-LAMP primers were designed according to the recommendations of 
Notomi et al. (2000) and Nagamine et al. (2002) for LAMP and loop primers respectively. 
Initially, RNA extracted from WHO 2
nd
 standard for HIV-1 was used at various dilutions 
42 
 
to test the primers and observe if the reaction could distinguish the different viral loads. 
Integrase-1 primers were designed against sub-type C as this is the predominant sub-type 
in South Africa (van Harmelen et al., 1999). Considering that the WHO standard is a sub-
type B isolate, RNA obtained from an ART-naïve patient was also applied in keeping with 
the South African viral load context. Similarly to the p24 primers, amplification was 
observed in the negative controls including no RT, no template and negative template 
controls (Fig. 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 RT-LAMP performed using the integrase-1 primer set, carried out at 60°C for 60 
minutes. The following sources of template RNA were used: WHO 2nd standard HIV RNA, 363 
000 copy dilution (3 ng)(lanes 1-2); WHO 2nd standard HIV RNA 10 000 copy dilution (38 ng) 
(lanes 3-4); RNA (82 ng) from patient H1 plasma (lanes 5-6); RNA from HIV negative individual 
N1 (3 ng) (lanes 7-8); no template control (lane 9); no RT control(lanes 2, 4 and 6).1.2% Tris-Boric 
Acid-EDTA agarose gel stained with GelRed nucleic acid gel stain. MWM: 100 bp GeneRuler™ (3 
µl). Electrophoresis performed at 100V for 60 minutes. Lanes contain 5 µl reaction products 
combined with 1 µl GelRed loading buffer. 
 
As was done in response to off-target amplification observed with the use of the p24 
primers, reagents RT, BSt Pol, dNTPs, betaine and MgSO4, were checked for 
contamination by excluding them from the reaction (Fig. 3.4).  
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Figure 3.4 RT-LAMP performed with integrase-1 primer set to determine source of persistent off-
target amplification in no template controls, carried out at 63°C for 60 minutes. The following 
reagents were excluded from the RT-LAMP reaction. RT (lane 1), Bst polymerase (lane 2), dNTPs 
(lane 3), betaine(lane 4), MgSO4 (lane 5). 1.2% Tris-Boric Acid-EDTA agarose gel stained with 
GelRed nucleic acid gel stain. MWM: 1Kb DNA ladder (3µl). Electrophoresis performed at 97V 
for 60 minutes. Lanes contain 5 µl reaction products combined with 1 µl 6X loading buffer. 
 
Amplification was not hindered by the exclusion of RT or betaine (Fig. 3.4). It was 
therefore assumed that the source of off-target amplification could be self-annealing 
primers. This is supported by the observation that the source is DNA, since amplification 
occurred in the absence of RT (Fig. 3.3 lanes 2, 4, 6; Fig. 3.4 lane 1). Increasing the 
reaction temperature from 60°C (Fig. 3.3) to 63°C (Fig. 3.4) did not prevent off-target 
amplification. 
 
3.2.3 Primer set 3, targeting integrase (Integrase II) 
A set of primers was designed against the integrase region of the Pol gene, against an HIV-
1 sub-type C reference sequence (GenBank accession no. AF286227). To screen these 
primers, RT-LAMP reactions were performed on RNA from ARV naive and treated 
individuals (Fig. 3.5).  
  
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 RT-LAMP performed with the integrase-2 primer set, carried out at 60°C for 60 
minutes. The following sources of RNA template were used: Treated HIV positive patient (144.41 
ng) (lane 1 and 2), treated HIV positive patient H3 (97 ng) (lane 3 and 4), HIV patient initiating 
treatment H5 (70 ng) (lanes 5 and 6), HIV patient initiating treatment H10 (37 ng) (lanes 7 and 8). 
No RT controls (lanes 2,4,6,8 and 10) and no template controls (lanes 9 and 10) were included. 2% 
TBE agarose gel stained with GR Green nucleic acid gel stain. MWM: 10 Kb DNA mass ruler (5 
µl). Electrophoresis performed at 90V for 60 minutes. Lanes contain 5 µl of reaction product 
combined with 1 µl 6X loading buffer. 
 
LAMP reactions were performed on cloned integrase DNA (Fig. 3.6). This was done as a 
control experiment to eliminate any problems that may arise from the use of patient-
derived RNA as well as single-step reverse transcription. As observed with the previous 2 
primer designs, off-target amplification was evident in the no template control and HIV-
negative control reactions (Fig. 3.5 lanes 9-10; Fig. 3.6 lanes 3-4).  
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Figure 3.6 LAMP performed using integrase-2 primer set at 60°C, for 60 minutes. Cloned 
integrase sequences FV20 (lane 1), and FV23 (lane 2) were used as template DNA. Lambda phage 
DNA (λ) was used as template in a negative control reaction (lane 3) along with a no template 
control (lane 4). 2% TBE agarose gel stained with GR Green nucleic acid gel stain. MWMa: DNA 
Mass Ruler (10kb) (3 µl); MWMb: 1Kb GeneRuler™ DNA molecular weight marker (3 µl). 
Electrophoresis performed at 100V for 60 minutes. Lanes contain 5 µl of reaction product 
combined with 1 µl 6X loading buffer. 
 
The use of negative control DNA, such as lambda phage DNA, aided in determining the 
source of off-target amplification. As seen in Figure 3.6 (lane 3), the intact presence of the 
HIV negative DNA reveals that the off-target amplification occurring in that reaction was 
not a result of off-target primer-template hybridisation. It was suspected that the off-target 
amplification was once again caused by primer dimerization. To identify this, LAMP was 
performed on no template controls with different combinations of the 4 primers, F3, B3, 
FIP and BIP based on the assumption that no amplification would be observed in the 
absence of the primer(s) engaging in dimerization (Fig. 3.7).  
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Figure 3.7 LAMP performed on no template controls using various combinations of integrase-2 
primers F3, B3, FIP and BIP to determine the source of off-target amplification carried out at 60°C 
for 60 minutes. Primer combinations: F3 and FIP (lane 1); B3 and FIP (lane 2); FIP and BIP (lane 
3); F3, B3 and FIP (lane 4); F3, FIP and BIP (lane 5); B3, FIP and BIP (lane 6); F3 and BIP (lane 
7); B3 and BIP (lane 8); F3, B3 and BIP (lane9). 2% TBE agarose gel stained with GR Green 
nucleic acid gel stain. MWM: 1Kb GeneRuler™ DNA ladder (4 µl). Electrophoresis performed at 
100V for 60 minutes. Lanes contain 5 µl of reaction product combined with 1 µl 6X loading buffer. 
Yellow: products of suspected i2FIP homo-dimerization, Red: products of suspected i2FIP-i2BIP 
hetero-dimerization. 
 
LAMP amplification products were evident in all reactions containing primer FIP (Fig. 3.7, 
lanes 1-6) which suggests that integrase-2 primer FIP (i2FIP) was responsible for the 
presence of off-target amplification using the integrase-2 primer set. Lane 3 (Fig. 3.7) 
consisting of the 2 40-meric primers, i2FIP and i2BIP, appears to display the same 
electrophoresis pattern evident in the presence of primers, i2F3 and i2B3 (Fig. 3.7, lanes 1, 
2 and 4), superimposed with other bands, even though neither of the smaller primers were 
included in this reaction. This suggests that the products formed in the presence of i2F3, 
i2B3 and i2FIP (yellow), are a result of i2FIP homo-dimerization, while the other bands 
present in lane 3 pertain to i2FIP-i2BIP hetero-dimerization (red) (Fig. 3.7).   
 
The original LAMP reaction included heating primer-template solutions to 95°C before 
addition to the reaction mixture. This was done to determine if the added heating step 
47 
 
would improve initial primer-target hybridisation and prevent the observed primer homo- 
and hetero-dimerization (Fig. 3.8). 
 
 
Figure 3.8 Testing effect of denaturing template and primers at 95°C prior to a LAMP reaction. 
LAMP carried out at a temperature gradient using integrase-2 primers. A) Cloned integrase FV23 
template DNA (lanes 1,3 and 5) and no template controls (lanes 2,4 and 6) were combined with the 
6 primers and heated at 95°C before addition to the LAMP reaction mixture performed at 55°C 
(lanes 1 and 2), 58°C (lanes 3 and 4) or 64°C (lanes 5 and 6) respectively for 60 minutes. B)Cloned 
integrase DNA template (lane 1), a lambda phage DNA negative control (lane 2) and no template 
control (lane 3)were combined with the 6 primers and heated at 95°C before addition to the LAMP 
reaction mixture and incubated at 60°C for 60 minutes. MWM: 1Kb GeneRuler™ (4 µl). 2% TBE 
agarose gel stained with GR Green nucleic acid gel stain. Electrophoresis performed at 100V for 60 
minutes. Lanes contain 5 µl of reaction product combined with 1 µl 6X loading buffer. 
 
 
Initially, amplification was only observed in the reactions containing integrase-DNA 
template (Fig. 3.8 A, lanes 1, 3 and 5) but not in the water blank (Fig. 3.8 A, lanes 2, 4 and 
6). However a repeat of the same reaction revealed amplification in the presence of HIV-
negative control template lambda phage DNA as well (Fig.3.8 B, lane 2) with both 
reactions producing identical electrophoresis bands, indicating that the amplification was 
off-target, which could not be prevented by an additional heating step or alternative 
incubation temperature. 
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3.2.4 Primer set 4 targeting HIV-1 isolate DU179 integrase (Integrase-DU179) 
A set of primers was designed using new online prediction tools. To eliminate the 
problems of screening primers using RNA obtained from patient plasma, a homogenous 
HIV-1 culture supernatant, isolate DU179, was acquired as a source of viral RNA from the 
Lynn Morris HIV Virology Lab, NICD, SA. The DU179 isolate was previously sequenced 
and primers were therefore designed for this specific isolate (GenBank accession no. 
AY043174.1.). The sequence was entered into the LAMP primer design software, primer 
explorer version 3. A combination of primer sets was provided from the software. Each set 
of primer sequences was analysed for primer-dimerisation on jPCR. No primer-dimers 
could be predicted for the following set and was therefore sent for oligo synthesis.  
 
Gradient RT-LAMP was performed to test the primers at a temperature range of 59°C to 
62°C, for 60 minutes. Amplification was observed only in the presence of HIV DU179 
template RNA (Fig. 3.9 lanes 7-9), but not in the no RT control (Fig. 3.9, lanes 4-6) and no 
template controls (Fig. 3.9, lanes 1-3). 
 
Figure 3.9 Gradient RT-LAMP to test integrase-3/DU179 primers using HIV-1 isolate DU179 
culture supernatant RNA (8708 nt) (lanes 4-9). RT-LAMP was performed for 60 minutes at: 59°C 
(lanes 1,4 and 7); 60°C (lanes 2,5 and 8); 62°C (lanes 3,6 and 9)and include no RT (lanes 4-6) and 
no template controls (lanes 1-3). MWM: 1 kb DNA ladder (4 µl). 2%TAE agarose gel stained with 
GR Green gel stain. Electrophoresis performed at 110V for 60 minutes. Lanes contain 5 µl of 
reaction product combined with 1 µl 6X loading buffer. 
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3.2.5 Restriction digestion analysis to determine specificity of primers to HIV-1 
Amplification products produced by RT-LAMP primed with the DU179-integrase primer 
set were analysed for specificity to HIV-1 by restriction digestion analysis. BSeXI was 
chosen for its recognition site spanning the gap between the F2 and F1 region of the 
forward inner primer, producing a 49 base pair stem-loop fragment and a 126 bp fragment 
spanning the F1 stem and downstream target. Agarose gel electrophoresis was performed 
to observe for these fragments (Fig. 3.10). 
 
Digestion with this enzyme changed the ladder-like electrophoresis pattern (Fig. 3.10, lane 
2) to 2 large bands (Fig. 3.10, lane 1), one around the expected size of 126 bp and another 
slightly larger, possibly as a result of incomplete digestion of large multiple stem-loop 
structures, suggesting that the amplification products are HIV specific. The integrase-
DU179 primer set was therefore selected for use in the viral load assay.  
 
 
Figure 3.10 BSeXI restriction digestion of RT-LAMP products primed by DU179-integrase 
primers. Digestion products (lane 1) and undigested RT-LAMP reaction.2% TBE agarose gel 
stained with GR Green nucleic acid gel stain. MWM: 50 bp DNA GeneRuler (4 µl). 
Electrophoresis performed at 90V for 90 minutes. Lanes contain 5 µl of digestion and RT-LAMP 
reaction product respectively. 
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3.3 Optimisation of reagents required for the RT-LAMP HIV-1 viral load assay 
3.3.1 Reverse Transcriptase 
It was found that in the presence of reverse transcriptase, the reaction changed colour from 
violet to blue prior to the start of the reaction, producing a false-positive result (Fig. 3.11). 
10 mMMgSO4 was used in these reactions as reactions usually remain violet above 9 mM 
MgSO4 (Goto et al., 2009). Yet this did not prevent the RT-induced colour change (Fig. 
3.11 and 3.12).When the amount of RT added to the reaction was reduced from 10 units to 
2 units, the reaction colour remained violet (Fig. 3.14).  
 
 
 
 
 
 
 
Figure 3.11 The effect of reverse transcriptase concentration on available Mg
2+
and reaction colour 
in p24-1 primed RT-LAMP reactions containing hydroxy-naphthol blue dye. Tubes1,3,5 and 7: 
10U AMV RT; Tubes 2,4, and 6: 0U AMV RT; Tubes 1-7: 10mM MgSO4.  
 
As previously identified during the primer design steps (section 3.2), use of the p24-1 
primer set produced off-target amplification (Fig. 3.1-3.3). Although amplification was 
evident in the no RT controls, these reactions remained violet in colour (Fig. 3.11) 
indicating that reactions which turned blue, including reactions performed with HIV RNA 
template and no template controls, did so as a result of the presence of RT. This was 
supported by the observation of reaction mixtures turning blue at the start of the reaction 
(Fig. 3.12). Also no difference could be observed in the reaction colours after 60 minutes 
(Fig. 3.12) which suggests that amplification by primer self-annealing did not produce 
enough Magnesium pyrophosphate (Mg2P2O7) to produce a colour change from violet to 
blue and therefore, in the context of the viral load assay, off-target amplification will come 
across as undetectable. 
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Figure 3.12 The effect of MgSO4 concentration (mM) on HNB-induced reaction colour in the 
presence (HIV RNA and no template controls) and absence of RT (no RT control). MgSO4 was 
added to reactions at a final concentration of 8, 8.5, 9 and 9.5 mM respectively. The reaction was 
performed using p24-1 primer set for 60 minutes at 63°C. 
 
3.3.2 Magnesium sulphate (MgSO4)  
The dye hydroxy-naphthol blue chelates with free metal ions of calcium and magnesium in 
solution, changing from violet to sky blue. In the RT-LAMP reaction, the dye interacts 
with the free Mg
2+
 ions produced during the reaction between MgSO4 and the phosphate 
group released during dNTP incorporation into the extending amplification products. It 
was previously determined by Goto et al. (2009) that the amount of MgSO4 added to the 
reaction affects the behaviour of HNB, whereby too little MgSO4 causes a premature 
colour change. It was confirmed earlier that off-target amplification does not produce a 
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colour change (Fig. 3.12). Therefore, a colour change produced by a no template control 
indicates an unstable dye interaction. No template control reactions were performed to test 
the lowest concentration of MgSO4 required for stable dye interactions (Fig. 3.13). 
  
 
 
 
 
Figure 3.13 The effect of MgSO4 concentration on colour of a LAMP reaction containing 
hydroxy-naphthol blue dye and no template DNA: 1) 0 mM MgSO4; 2) 5 mM 3) 6 mM 4) 7 mM. 
 
The results of Goto et al. (2009) were confirmed in this study (Fig. 3.13) and it was 
determined that the HNB reaction remained stable with the use of 6-8mM MgSO4, since at 
these concentrations the reaction remained violet in colour  in the absence of RT (Fig. 3.12 
and 3.13 tubes 3-4), the correct colour for a no-template negative control. Goto et al. 
(2009) determined that MgSO4 above 9 mM prevented a colour change in positive 
reactions and therefore 8 mM was selected as the highest acceptable concentration. The 
blue colour of the reaction without MgSO4 is indicative of the colour change that takes 
place once free Mg
2+ 
ions are consumed. 
 
Following determining stable concentrations of MgSO4, RT LAMP was performed using 
7mM MgSO4 to determine the effect of reducing RT from 10 Units to 2 Units on the HNB-
induced reaction colour (Fig. 3.14). The integrase-2 primer set, which produces off-target 
amplification, was used and no colour change was observed, which is the expected result 
for stable dye interactions following off-target amplification (Fig. 3.14). Therefore, the 
optimal RT amount was accepted as 2 units. 
 
 
 
 
 
 
Figure 3.14 The effect of reverse transcriptase (RT) concentration on reaction colour of integrase-2 
primed RT-LAMP reaction containing Hydroxy-naphthol blue dye. Reactions contain 7 mM 
MgSO4 and 2 U AMV RT. RT-LAMP was performed at 60°C. HIV-infected plasma-derived RNA 
(tubes 1 and 3) and HIV standard RNA (tubes 2 and 4) were added to the RT-LAMP reaction 
alongside RT negative (tubes 3, 4 and 6) and no template controls (tubes 5 and 6). 
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3.3.3 Hydroxy-naphthol blue 
As seen with the use of the first 3 primer sets, the reaction colour remained violet for all 
reactions, despite the definite presence of amplification on the agarose gels. Given that 
self-primed off-target amplification is not as efficient as amplification as a result of 
hybridisation with the target template, it was hypothesised that the colour change would 
only take place once a threshold of magnesium pyrophosphate was produced. This was 
tested by increasing the amount of self-annealing primer FIP from the integrase-2 set 
(i2FIP) (section 3.2.3), expecting to speed up the accumulation of magnesium 
pyrophosphate to produce a colour change (Fig. 3.15-3.18).  
 
Reactions containing lower amounts of i2FIP (0-1.6 µM) did not change colour after 60 
minutes whereas reactions with higher amounts of i2FIP (3.6-16 µM) did change from 
violet to blue (Fig. 3.15). The colour change was solely indicative of rate of increase in 
amplification, and not as a result of a premature colour change or heating the reaction 
mixture, as all reactions remained violet at the start of the reaction as well as 5 minutes into 
the reaction respectively (Fig. 3.15). 
 
To confirm that production of the Mg2P2O7 by-product only produced a colour-change 
after reaching a threshold of amplification, LAMP reactions performed with different 
amounts of the self-annealing i2FIP primer were analysed for by-product (Fig. 3.16).There 
was no magnesium pyrophosphate precipitate at the start of the reaction but was present in 
both the violet (1.6 µM i2FIP, Fig. 3.15 and 3.16) and blue tubes (3.6 µM, Fig. 3.15 and 
3.16) after 60 minutes of RT-LAMP incubation (Fig. 3.16).  
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Figure 3.15 Effect of different amounts (µM) of i2FIP primer-template on HNB-induced colour 
progression for 5 minute and 60 minute LAMP reactions respectively. 0 min: Reaction colour at the 
start of the reaction. Reaction performed with 7mM MgSO4. 
 
As determined in section 3.3.1, where the effect of MgSO4 concentration on HNB-induced 
colour change was investigated, optimal MgSO4 concentration occurred within the range of 
6 mM – 8 mM, and the lower the concentration, the earlier a colour change was expected. 
Therefore, the HNB interactions were also tested in the presence of 6 mM MgSO4 (Fig. 
3.17).  
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Figure 3.16 RT-LAMP reaction tubes viewed under white light to aid identification of the white 
Mg2P2O7 amidst the blue or violet reaction mixture. The shaded areas indicated by arrows represent 
Mg2P2O7 precipitate produced as the reaction progresses. No precipitate was present at the 
beginning of the reaction (5 min.). 
 
The results were the same as that observed using 7 mM MgSO4 (Fig. 3.15), whereby 
amounts of 0-1.6 µM i2FIP primer did not change colour after 60 minutes and reactions 
using 3.6-16 µM i2FIP primer  did change from violet to blue (Fig. 3.17). The lack of a 
colour change at the start of the reaction as well as 5 minutes into the reaction indicated 
that the colour change was solely the result of rate of increase in amplification (Fig. 3.17). 
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Figure 3.17 Effect of addition of different amounts (µM) of self-annealing forward inner primer-
template (i2FIP) on HNB induced colour progression, using 6mM MgSO4. 
 
To further emphasise that the amount of FIP added affected the rate of amplification, 
agarose gel electrophoresis was performed using a DNA stain that produces increasing 
fluorescence with increasing amount of DNA present in the gel, this together with a 
corresponding set of mass standards (mass ruler) (Fig. 3.18). LAMP amplification product 
on the gel increased in brightness with increasing addition of template i2FIP primer, 
indicating an increase in mass (ng) for products of the same length (bp) (Fig. 3.18) 
. 
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Figure 3.18 Amplification products as a result of RT-LAMP performed with increasing 
concentration of integrase-2 forward inner primer (i2FIP) primer-template. FIP concentration 
(µM): 0µM (Lanes 1-2); 1.6 µM (Lanes 3-4); 3.6 µM (Lanes 5-6) and 16 µM (Lanes 7-8). 2% TAE 
agarose gel stained with GR Green nucleic acid stain. MWM: 10Kb Mass Ruler™ DNA ladder (5 
µL). ng: nanogram mass of reference ladder bands. Electrophoresis performed at 90V for 90 
minutes. Lanes contain 5 µl of reaction product combined with 1 µl mass ruler loading dye. 
 
3.3.4 Analysis of the colour change in response to HIV-1 amplification 
RT-LAMP was performed using the integrase-DU179 primer set according to the 
conditions identified earlier (Section 3.3.1-3.3.3) for favourable HNB dye interactions. 
Specifically, the reaction was performed in the presence of 2U reverse transcriptase and 8 
mM MgSO4. After a 60 minute reaction at 60°C, the reaction was inactivated  at 85°C for 5 
minutes resulting in a pale blue reaction colour in the reaction containing HIV DU179 
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RNA (Fig. 3.19.1), whereas no colour change was observed in the no template control 
(Fig. 3.19.2) and RT negative controls (Fig.3.19.3) respectively.  
 
 
 
 
 
 
Figure 3.19 Reaction colour observed after performing RT-LAMP with integrase-DU179 primers 
at 60°C for 60 minutes. Reaction containing HIV DU179 RNA (tube 1), no template control (tube 
2) and no RT control (tube 3). 
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Chapter 4 
Discussion 
Disease progression-monitoring in the HIV-infected population is a large contributor to 
successful treatment programmes. Various studies prove that HIV viral load is the most 
superior biomarker of identifying treatment failure and progression to AIDS and AIDS-
related death (Mellors et al., 1997; Jourdain et al., 2013). However, the available 
commercial tests based on real time RT-PCR are expensive and complex. Viral load tests 
cannot be performed on-site at primary health care clinics. The complications of lengthy 
sample transport, the turn-around-time to result and the difficulty faced by patients in 
resource-limited settings to commit to follow-up emphasise the dire need for rapid, simple, 
on-site disease progression-monitoring, also referred to as point-of-care. Hence, the aim of 
this project was to develop a point-of-care test specifically by applying the novel reverse-
transcription loop-mediated isothermal amplification technique, utilising hydroxy-naphthol 
blue colorimetric detection for semi-quantitative determination of HIV-1 viral load.  
 
When compared to current low-cost strategies, such as RT activity assays and the LTR 
assay, RT-LAMP appeared most feasible as it has a rapid turn-around time and can be 
converted into a miniaturised, single step procedure, only requiring a heating block and 
centrifuge. Such advantages to the RT-LAMP assay have been applied in the production of 
non-commercial diagnostic assays for various infectious agents, but there is no HIV-1 viral 
load test existing in this format, and as such the foundational technology for an RT-LAMP 
assay needed to be developed. 
 
Assay development is a multi-faceted procedure. As all aspects of the assay function in 
unison to achieve the purposed result, it was particularly challenging to systematically 
optimise individual reagents and conditions in isolation. Two essential areas where most of 
the effort was expended upon was in acquiring optimal viral template RNA; and then 
subsequently troubleshooting the somewhat complicated primer design. Despite these 
challenges and setbacks, a number of developments were achieved, and these are discussed 
below.  
 
4.1.  Template RNA acquisition 
Various approaches were taken to obtain reasonable quality patient-sourced HIV RNA. 
RNA is easily degraded due to the abundance of RNA-nucleases in the environment. Since 
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the commercialisation of real time PCR viral load tests, numerous validations have been 
performed to determine how various plasma isolation and RNA extraction procedures 
affect the viral load result. We found that consistent quality was achieved by isolating 
plasma in serum separator tubes, followed by concentration of viral particles in 1ml of 
plasma by centrifugation. The resultant pellet is resuspended in PBS and applied to the 
Qiagen viral RNA procedure. These findings compared well with other studies. For 
example, PBS has been validated as an acceptable medium for altering sample input 
volume without compromising quantification (Mine et al., 2013). The use of gel-barrier 
tubes, such as serum separator and plasma separator tubes have been shown to improve 
RNA recovery (Ginocchio et al., 1997). The observed effects of plasma storage on RNA 
recovery agreed with the literature whereby samples are stored stably at -70°C (Ginocchio 
et al., 2007). As freeze-thaw cycles also affect stability (Ginocchio et al., 1997) plasma 
was therefore stored as 1 ml aliquots to avoid more than one freeze-thaw cycle.  
 
4.2.  Primer design and specificity to HIV-1 
Key to the isothermal nature of RT-LAMP is the complex primer design whereby, 
following ~20 nucleotide portion of the inner primer hybridising to the target, the primer’s 
5’ overhang loops back to bind to extending daughter DNA strand, catalysed by BSt 
polymerase (Notomi et al., 2000). Ultimately, primer design involves 4 primers 
corresponding to 6 regions of 1 target gene (Notomi et al., 2000), and an additional 2 
primers that will hybridise to loop regions following initial amplification steps (Nagamine 
et al., 2002).  
 
Although essential to the functionality of the technique, LAMP primer interactions are 
problematic and often prone to form off-target, self-primed amplicons (Gandelman et al., 
2011; Curtis et al., 2009). It was therefore thought logical to apply a set of primer 
sequences which have already proved successful. A set of LAMP primers targeting the p24 
region of the Gag gene, designed by Curtis et al. (2008) were tested for application in this 
viral load assay. The off-target amplification demonstrated here was similar to that 
observed by Curtis et al. (2009), which appeared to be products of primer homo- or hetero-
dimerisation in the no template controls. However, they nevertheless demonstrated 
amplification of HIV RNA in the presence of both in vitro transcribed RNA and that 
obtained from patient samples. Yet no amplification of p24 RNA could be achieved in the 
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present study, wherein all electrophoretic bands appeared identical to the off-target 
amplification products, even though various sources of template were used. 
 
Off-target amplification cannot be tolerated in a diagnostic assay, as it may lead to a false-
positive result and therefore high levels of specificity are required. Hence, primer sets were 
tested not only in the presence of HIV RNA but alongside negative controls, such as no 
template controls (also referred to as water blanks) and reactions containing RNA obtained 
from HIV negative individuals or lambda phage DNA. This helped to ascertain off-target 
amplification produced by the first 3 primer sets as well as permit further testing with the 
fourth primer set, in which no template controls lacked any amplification.  
 
The specificity of LAMP and RT-LAMP is considerably higher than conventional PCR as 
optimal binding of all six primers is required to bring about LAMP amplification of the 
desired target. Primer-target sequence identity of at least 90% is recommended (Zhang et 
al., 2010). In the context of HIV, however, this becomes problematic as the virus has no 
replication proof-reading capacity and is likely to mutate from progeny to progeny, the 
common cause of ART drug resistance. This may reduce the sensitivity of the RT-LAMP 
viral load assay, as certain strains of virus may not amplify, causing an underestimated 
viral load or false negative result (Wojewoda et al., 2013). The effect of genetic 
heterogeneity on sensitivity was reported by Curtis et al. (2008; 2009) whereby different 
amplification sensitivities were observed for detection of a homogenous viral load panel 
(as low as 12 copies HIV RNA) (Curtis et al., 2009) and patient samples (no less than 500 
copies) (Curtis et al., 2008). High levels of genetically diverse viral strains can evolve in a 
single patient (Neher and Leitner., 2010; Lee et al., 2008), and may explain why, when 
using the p24 primers here, only off-target amplification occurred and no HIV was 
detected. This needn’t be a drawback when using the assay in a semi-quantitative manner, 
where the desired detection limit is 1 000 copies. Still, the p24 primers failed to detect 
more than 1 000 copies of the WHO standard, a homogenous isolate, but this may have to 
do with the questionable quality of the RNA extracts.  
 
Analysis of the RT-LAMP amplicons produced by the first 3 primer sets revealed identical 
electrophoresis patterns in negative controls and experimental reactions. This suggests that 
there was no binding to the template RNA or DNA by the first 3 primer sets. This was 
particularly unexpected with the use of the integrase-2 set in the presence of 2 integrase 
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clones. Although the clone sequences have 99% sequence identity with the integrase-2 
primers (Appendix D), the subsequent amplification products were the same as those 
produced in the presence of lambda phage DNA or water.  
 
Despite the strong sequence identity between the integrase clones and the integrase-2 
primer set, binding to the target was prevented by self-priming within the forward-inner-
primer of integrase-2 (i2FIP). This means only 5 of the 6 primers were available to bind to 
the target, which is not enough for LAMP amplification. Surprisingly, the i2FIP primer 
displayed higher self-affinity than affinity for the target sequence. This was evident as 
amplification did not occur in the absence of this single primer, but was present even in 
reactions from which all other primers and nucleic acid was excluded. These results were 
consistent whether in the presence of DNA or RNA, and whether reverse transcriptase was 
included or not.  
 
Thus far it became clear that it was essential to stringently screen all primer sequences for 
any homo- or hetero-dimer sites before selecting for synthesis. This was done for the 
fourth primer set. Furthermore, to eliminate failure due to mismatches between the primers 
and target, the primers were designed specifically for the DU179 isolate, available as a 
tissue-culture supernatant. There are considerable differences between the use of culture 
supernatant and the testing of patient-derived RNA in the clinical setting. Culture 
supernatant is purer, lacking the proteins and molecules that are common in both healthy 
and diseased individuals that often complicate RNA extraction procedures. The culture-
supernatant contains viral particles of a single isolate, here DU179 was used, consisting of 
very minimal genetic heterogeneity if any, whereas that of patients cannot be predicted. 
Originally, the most plausible strategy seemed to be to use patient-derived RNA so as to 
imitate the expected clinical pressures under which the assay would need to perform, but 
many problems were encountered with acquisition of RNA from patient plasma.  
 
The difficulties with patient plasma-derived RNA included low yields(Table F1). Low 
yields of extracted RNA are common for cell-free fluids (Bustin et al., 2009). Variability in 
the Qiagen viral RNA kit has been reported previously (Fransen et al., 1998; Fanson, 
Osmack and Bisceglie, 2000; Monleau et al., 2009), yet in other cases the kit displayed 
superior reproducibility (Verhyden et al., 2003). RNA-dependent procedures are generally 
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fragile, the complexities of which do affect efficient, established routine testing (Aguilera 
et al., 2000). 
 
Although part of the investigation required optimising acquisition of patient plasma-
derived RNA, the aim was not to develop RNA extraction methodologies but rather RT-
LAMP based HIV RNA quantification. The use therefore of the DU179 derived RNA and 
DU179 specific primers allowed for progress in the development of other aspects of the 
RT-LAMP assay that seemed hindered with the use of other sources of RNA (Appendix 
F). No homo- or hetero-dimer sites could be identified by the jPCR program for the DU179 
primer set. As expected, this primer set successfully hybridised to the DU179 RNA, 
evident as the ladder-like banding pattern by subsequent gel electrophoresis. Product 
positivity was confirmed by target-specific restriction digestion. The presence of extra 
bands in the electrophoresis pattern following restriction digestion of LAMP products is 
thought to represent incomplete digestion due to the presence of multiple stems and loops 
(Le Roux et al., 2009). 
 
4.3.  RT-LAMP optimisation 
A) Effect of magnesium and AMV RT on colour change 
Following identification of a suitable set of primers for the assay, further development 
could take place. The general reaction conditions necessary for RT-LAMP amplification 
are well defined in the literature. Therefore, further optimisations only included conditions 
which specifically affected amplification detection by hydroxy-naphthol blue dye and the 
semi-quantitative nature thereof. Such parameters included optimising MgSO4 
concentration and reverse transcriptase. The findings are summarised in Table 4.1. In 
accordance with that observed by Goto et al. (2009) and Hadersdorfer et al. (2011), the 
colour change was found to be optimal at a final concentration of 6-8 mM MgSO4. Since 
the colour change is related to free Mg
2+
 depletion, it is also affected by dNTP 
concentration (Zippelius et al., 2000; Goto et al., 2009). During extension of a DNA strand, 
Mg
2+
 forms complexes with the dNTP’s (Zippelius et al., 2000). Since a longer template 
would use more dNTP’s, the upper MgSO4 limit of 8 mM was applied for the use of HIV 
amplification. While lower concentrations such as 6-7 mM favour an earlier colour change 
(Goto et al., 2009) and prevent off-target amplification (Liu et al., 2013a), concentrations 
below 8 mM can hinder amplification (Tsai et al., 2009). The lower limit of 6-7 mM 
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MgSO4 was sufficient for the HNB interaction investigations where a 40 bp primer was 
applied as DNA template.  
 
The RT effect may also be due to the use of Mg
2+
 and dNTP’s during cDNA synthesis. 
Additionally, the RT effect may be specific to the type of RT used. It is generally 
recommended to perform RT-LAMP with 10 units of AMV RT, but this produced a colour 
change prior to the start of the reaction, which is a false-positive result. Instead, the amount 
of AMV RT was reduced to 2 units, wherein the reaction colour remained violet prior to 
incubation. The use of 2 units has previously proved to be sufficient for RT-LAMP 
amplification of HIV in the absence of HNB (Curtis et al., 2009). In another reported 
study, the use of 20 units of Superscript III RT did not produce a premature colour change 
(Hadersdorfer et al., 2011). Although not confirmed, the interaction between HNB and RT 
may be due to the presence of alkaline-earth metals in the RT carrier buffer.  
 
B) RT-LAMP reaction temperature 
Reaction temperature in nucleic acid testing requires stringent control. In PCR, an incorrect 
primer annealing temperature can cause off-target amplification or prevent target 
amplification. Essentially, RT-LAMP is performed optimally at the annealing temperature 
of the F3 and B3 primer sequences (Notomi et al., 2000). For this reason, some primer sets 
were subjected to RT LAMP incubation at a temperature as low as 55°C, though generally 
RT-LAMP is performed between 60°C and 65°C. In accordance with other LAMP 
applications (Liu et al., 2013a), the RT-LAMP reaction was found to be quite robust with 
regards to temperature across all 4 primer sets. Specifically, the first 3 sets, excluded due to 
off-target amplification, performed consistently at different incubation temperatures. The 
DU179 primers successfully amplified HIV at 59°C, 60°C and 62°C (Table 4.1). The 
robustness of the reaction makes it more flexible for field use applications where the 
heating source may fluctuate by a few degrees (Kubota et al., 2013) and will therefore also 
have fewer calibration demands than a thermocycler, for example. 
 
Table 4.1 Optimum RT-LAMP reaction parameters for use with hydroxy-naphthol blue detection 
and primers targeting integrase. 
Parameter Optimum amount 
MgSO4 8 mM 
AMV RT or Thermoscript RT 2 units 
Incubation temperature 59°C, 60°C and 62°C 
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4.4.  Mechanisms of hydroxy-naphthol blue amplification detection 
The colorimetric result read-out of the proposed RT-LAMP assay is based on the 
interaction between hydroxy-naphthol blue dye and the RT-LAMP by-product, magnesium 
pyrophosphate. As dNTPs are added to the growing RT-LAMP products, the released 
phosphate group binds to free magnesium ions donated by magnesium sulphate, forming 
Mg2P2O7. Therefore the by-product accumulates as the target nucleic acid is amplified. 
This produces turbidity in the reaction mixture, that when measured in real time is directly 
proportional to amplification rate (Mori et al., 2004).  
 
The rate of PCR amplification is dependent on template amount. Similarly, it has also been 
demonstrated that LAMP amplification rate can be correlated with template quantity (Le 
Roux et al., 2009; Zhang et al., 2010). The coupling of a turbidometer to a LAMP reaction 
in real-time can therefore be used to determine viral load (Le Roux et al., 2009). Thus, as 
such, it was investigated here whether the amplification rate could then be correlated with 
the dynamics of the hydroxy-naphthol blue dye. In the absence of a source of known HIV 
template copy number, the previously identified self-annealing primer i2FIP was applied as 
a copy-number-controllable template. A definite correlation between initial i2FIP 
concentration and colour change from violet to blue was observed, supporting the 
suggestion that HNB can behave semi-quantitatively. This was also seen in qualitative, 
diagnostic applications of HNB detection of LAMP products, whereby assessing copy 
number sensitivity of these assays showed that reaction with higher amount of template 
displayed brighter blue colour change than that of lower copy numbers (Wang et al., 
2012).This indicates that the application of the HNB dye to a semi-quantitative context was 
successful. Also the amount of i2FIP included in a conventional LAMP reaction (1.6 µM) 
did not produce a colour change after 60 minutes, indicating that self-primed amplification, 
common in LAMP reactions (Curtis et al., 2009) is unlikely to create a false-positive 
colour change by HNB. This suggests that HNB detection is more suitable than DNA 
intercalating dyes such as Sybr Green or Pico Green, which will detect any double-
stranded DNA produced in a reaction.  
 
The limitations of the use of i2FIP should however be considered: i2 FIP is a deoxyribo-
oligomer only 40 nucleotides long. Specific use of the dye in the context of HIV RNA 
template averaging 470 nucleotides, and the associated reverse transcription dynamics, is 
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yet to be determined. However, Ma et al. (2010) observed a similar effect whereby HNB 
colour change took place at a threshold RT-LAMP detection of 60 copies H1N1 RNA, 
despite the presence of turbidity in violet reactions of lower copy number. 
 
In the present study, once the HNB optimisations were applied to the HIV-DU179 sample, 
a colour change from violet to faint blue was observed after 60 minutes. This was a 
promising result as it suggests that the HNB-colour change dynamics may be applicable to 
the reverse transcription LAMP reaction, and not just in DNA amplification. However, the 
exact viral load of the culture supernatant was unknown but expected to be high, since 
tissue culture has been applied previously to permit viral replication under controlled 
conditions. 
 
Further work was then required to determine the time-to-positive: the required RT-LAMP 
incubation time at which the colour change from violet to sky-blue is indicative of a HIV 
viral load ≥ 1 000 copies/ml. Current viral load tests provide absolute counts of viral copy 
number. However, this is not necessary for disease progression-monitoring, as seen in 
studies where by prediction of disease progression is achievable by placing patients within 
viral load ranges (Mellors et al., 1997). This basically implies that a patient having a viral 
load of 600 copies per ml has the same prognosis as a patient with a viral load of 800 
copies per ml, as both fall in the category of above 500 copies. Similarly, two patients 
undergoing ART whose viral load changes from undetectable to 1 860 copies and 
undetectable to 900 respectively, will both be considered to have undergone treatment 
failure and would be managed accordingly. This provides more options in terms of 
designing resource-limited assays, and suggests that, though possibly limited in its inability 
to identify absolute viral load, the technique is still clinically relevant.  
 
Currently, viral load control panels only exist in the form of sub-type B and would not be 
fitting for an assay developed for sub-type C. Instead, whole blood of 10 HIV-infected 
individuals was collected for the RT-LAMP assay and for routine viral load testing 
simultaneously. The routine viral load results were then used as a reference for further 
development of the assay, whereby the subsequently extracted RNA was diluted to obtain a 
range of copy numbers. Use of these samples, however, produced inconclusive results 
which appear to be due to the return of non-specific amplification withtin the reaction 
(Appendix F). It can also be questioned as to whether inhibition of an aspect of the RT-
67 
 
LAMP reaction occurred as a result of co-extracted inhibitory molecules occurring in 
plasma. This is supported by the observation that use of patient-derived RNA proved 
problematic throughout the development of the assay Alternatively, a sub-type C viral load 
control panel would have to be synthesized by cloning of HIV-1 DNA and performing in 
vitro transcription to produce RNA. The advantage of this is that the synthesized RNA can 
be controlled for copy number and diluted to make up a viral load panel. The panel can 
then be used to perform RT-LAMP for a range of durations to determine the incubation 
duration for which panel members of ≥ 1 000 copies/ml could be distinguished by colour 
change from violet to blue. This should then be followed by validation on patient samples 
of unknown viral loads to determine the positive and negative predictive values of the RT-
LAMP HNB viral load assay, compared with results obtained from simultaneous viral load 
real-time RT-PCR testing. 
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Chapter 5 
5.1 Conclusion 
This study represents the initial steps of assay development of a novel reverse-transcription 
loop-mediated isothermal amplification (RT-LAMP) viral load test, with a semi-
quantitative, colorimetric result read-out. Aspects of assay development which were 
completed included the design of RT-LAMP primers against the integrase region of the pol 
gene, optimisation of reaction conditions including MgSO4 concentration, reverse-
transcriptase amount, reaction temperature, as well as the demonstration of the semi-
quantitative capacity of the hydroxy-naphthol blue dye. The progress made towards 
development of the assay is summed up in the demonstration of the qualitative detection of 
the HIV-1 DU179, evident as a HNB-induced colour-change from violet to blue while the 
employed negative controls remained violet, following application of the optimisations that 
were carried out. The use of patient-derived RNA did not, however produce the same result 
and as such further considerations and optimisations are required to better suit the assay for 
use on patient samples. 
 
5.2 Future work and considerations 
RT-LAMP at the point-of-care 
Due to the appeal of the LAMP and RT-LAMP formats to resource-limited settings, 
development of point of care heating-devices and lab-on-chip cartridge formats able to 
support the LAMP reaction are becoming more and more prevalent. The reagents can be 
lyophilised, easing the requirements for kit storage (LaBarre et al., 2011). Of particular 
interest is the development of non-instrumented, nucleic acid amplification (NINA) 
heating devices which rely on heat produced by an exothermic chemical reaction instead of 
electricity (LaBarre et al., 2011; Curtis et al., 2012; Kubota et al., 2013). NINA devices can 
achieve LAMP incubation temperatures with the use of boiling water in an ambient 
environment (Kubota et al., 2013). Similarly, there is a rise in sample collection 
development such as dried blood spots (Johannessen et al., 2009) and plasma separating 
devices that abrogate the need for a centrifuge (Liu et al., 2013b). 
 
Recommendations for field use 
RT-LAMP assays generally boast high specificity but this equates to low sensitivity in the 
context of the viral genetic heterogeneity characteristic of HIV-1, which could mean a poor 
positive-predictive value in some patients (Wojewoda et al., 2013). A simple means to 
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increase the positive-predictive value of the assay is to combine an undetectable result with 
other routine surrogate markers accessible at primary healthcare centres, such as 
haemoglobin and body mass index. An individual with notable changes in the surrogate 
markers but no corresponding RT-LAMP viral load change could be eligible for more 
sensitive, off-site tests including real time RT-PCR, CD4 count or even resistance 
screening in the case where a false-negative is suspected.   
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Appendix B: Materials 
RNA extraction:  
WHO 2nd International Standard for HIV-1 97/650 (NIBSC, Hertfordshire, UK) 
lyophilized human plasma reconstituted in SABAX dH2O (Adcock Ingram, Midrand, 
South Africa) (1 ml), stored at -20°C, (50 µl aliquots). 
Phosphate Buffered Saline (PBS) pH 7.4 (0.01 M) (Sigma-Aldrich, St Louis, USA) 1 
tablet, dH2O (200 ml) (0.0027 M potassium chloride, 0.137 M sodium chloride), stored at 
4°C. 
Carrier RNA (Qiagen, Hamburg Germany) (1 µg/µl) carrier RNA (310 µg), Buffer AVE™ 
(310 µl), aliquotted (12 µl), stored at -20°C. 
Buffer AVE™ (Qiagen, Hamburg Germany) RNase-free dH2O, 0.04% Sodium Azide. 
Buffer AVL™ (Qiagen, Hamburg Germany) proprietary, contains guanidine thiocyanate. 
Buffer AW1™ (Qiagen, Hamburg Germany) proprietary, contains guanidine 
hydrochloride, 100% EtOH (molecular grade) (Sigma-Aldrich, St Louis, USA). 
Buffer AW2™ (Qiagen, Hamburg Germany)proprietary, contains sodium azide, 100% 
EtOH (molecular grade) (Sigma-Aldrich, St Louis, USA). 
 
LAMP and RT-LAMP: 
10X DNA polymerase Buffer B (Lucigen, Middleton, USA) Tris-HCl (20 mM), 
(NH4)2SO4 (10mM), MgSO4 (2mM) and 0.1% Triton X-100. 
Hydroxy-naphthol blue (HNB)(3 mM) filter-sterilised (0.2 µm): HNB (SAS Chemical, 
Mumbai, India)(17.955 mg), 0.1% DEPC-treated dH2O (10 ml). 
DEPC-treated dH2O (0.1%) autoclaved: Diethylpyrocarbonate (Sigma-Aldrich, St Louis, 
USA) (1 ml), dH2O (1 L).  
 
Restriction digestion: 
10X BSeXI Buffer (Thermo Scientific, Massachusetts, USA) Tris-HCl (50 mM; pH 7.5), 
MgCl2 (2 mM), NaCl (100 mM), BSA (0.1 mg/mL). 
 
Agarose gel electrophoresis:  
Tris – Boric Acid – EDTA Buffer (TBE) (5X) TrisHydroxy-methyl aminomethane (27 g), 
Boric Acid (13.75 g), EDTA (2.325 g), distilled water (500 ml).  
1X TBE 5X TBE (100 ml), distilled water (400 ml). 
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Tris – acetic acid – EDTA Buffer (TAE) pH 7.6 (10X) Tris Hydroxy-methyl 
aminomethane (96.88 g), Sodium acetate.3H2O (13.6 g), EDTA (7.44 g), dH2O (2 L). 
1X TAE 10X TAE (100 ml), dH2O (900 ml). 
1kb GeneRuler working solution 1Kb GeneRuler (Thermo Scientific, Massachusetts, 
USA) (1 µl), 6X Loading dye (Thermo Scientific, Massachusetts, USA) (2 µl), nuclease-
free distilled water (Thermo Scientific, Massachusetts, USA) (9 µl). 
6X DNA Loading dye (Thermo Scientific, Massachusetts, USA) 10 mM Tris-HCl (pH 
7.6),   0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM EDTA 
2% Agarose gel Agarose (Lonza) (1.2 g), 1X TBE/TAE (60 ml), GR Green Nucleic Acid 
gel stain (Clare Chemical) (6 µl). 
1.2% Agarose gel Agarose (Lonza) (0.72 g), 1X TBE/TAE (60 ml), GR Green Nucleic 
Acid gel stain (Clare Chemical) (6 µl). 
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Appendix C: Primer sequences 
Table C1. The 6 primers sequences of each of the 4 RT-LAMP primer sets used for the 
development of the RT-LAMP-based viral load assay. Italics indicate linkers recommended by 
Notomi et al. (2000) 
Target gene Primer sequence (5’-3’) 
p24 (Gag) 
(Curtis et al., 
2008) (Inqaba 
Biotechnologies, 
Pretoria, South 
Africa) 
 
Integrase-1 
(University of 
Cape Town, 
Cape Town, 
South Africa) 
 
 
Integrase-2 
(Inqaba 
Biotechnologies, 
Pretoria, South 
Africa) 
 
 
Integrase/DU179 
(University of 
Cape Town, 
Cape Town, 
South Africa) 
 
FIP  CAGCTTCCTCATTGATGGTTTCTTTTTAACACCATGCTAAACACAGT 
BIP TGTTGCACCAGGCCAGATAATTTTGTACTGGTAGTTCCTGCTATG 
F3  ATTATCAGAAGGAGCCACC 
B3  CATCCTATTTGTTCCTGAAGG 
Loop F  TTTAACATTTGCATGGCTGCTTGAT 
Loop B  GAGATCCAAGGGGAAGTCA 
 
FIP TTCTTTAATTCTTTATTCATTTTTCAGGTATCCAACAGGAATTT 
BIP ACATACAAACTAAAGAACTATTTTTTTCCAAATAGGGTCTCTGC 
F3 TTTCACCAGTGCTGCAGTTAAGGCA 
B3 ACTACTGCCCCTTCACCTTTCCA 
Loop F TACTACTCCCTGACTTTGGG 
Loop B AATTCAAAATTTTCGGGTTTATT 
 
FIP TCTTTATTCATGGATTCTAATTACATACAGACAATGGCAGT 
BIPAAAAGGGGGGATTGGGGGGTAAAAGGGTCTCTGCTGTCTC 
F3 ACTAAAATTAGCAGGAAGATGGC 
B3TTATGTCACTGTTATCTTGTATTACT 
Loop FTGGGGATTGTAGGGAAT 
Loop BCAGGGGGGAAAGAATAATAGATA 
 
FIP GATACCTGCCCACCAACAGGTTTTAGACAATGGTAGTAATTTCAC 
BIPAATTCCCTACAATCCCCAAAGTCTTTTTCTTACCTGTCCTATGATT 
F3ACTAAAATTAGCAGGAAGATGGC 
B3 TGGAAAGGTGAAGGGGCAGTAGT 
Loop F  GCCTTAACTCTAGCACTGG 
Loop B GGAGTAGTAGAATCCATGAATAAAGAATT 
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Appendix D: Integrase clone sequence identity to integrase-2 primers 
Regions of primer hybridisation are underlined and mismatches highlighted in grey. 
>FV20  
TTTCTAGATGGAATAGATAAGGCTCAAGAAGAGCATGAAAAATATCATAGCAATTGG
AGAGCAATGGCTAGTGAGTTTAATCTGCCACCCATAGTAGCAAAAGAAATAGTAGCTA
GCTGTGATAAATGTCAATTAAAAGGGGAAGCCACACATGGACAAGTAGACTGTAGCC
CAGGGATATGGCAATTAGACTGTACACATTTAGAAGGAAAAATCATCCTGGTAGCAGT
CCATGTAGCCAGTGGCTACATAGAAGCAGAGGTTATCCCAGCAGAAACAGGACAAGA
AACAGCATACTATATACTAAAGTTAGCAGCAAGATGGCCAGTCAAAATAATACATACA
GACAATGGCAGCAATTTCACCAGTGCTACAGTTAAGGCAGCCTGTTGGTGGGCAGGTA
TCCAACAGGAATTTGGAATTCCCTACAATCCCCAAAGTCAGGGAGTGGTAGAATCTAT
GAATAAAGAATTAAAGAAAATCATAGCACAAGTAAGGGATCAAGCTGAACATCTTAA
GACAGCAGTACAAATGGCAGTATTCATTCACAATTTTAAAAGAAAAGGGGGGATTGG
AGGGTACAGTGCAGGGGAGAGAATAATAGACATAATAGCAACAGACATACAAACTAA
AGAATTACAAAAACAAATTTTAAAAATTCAAAATTTTCGGGTTTATTACAGAGACAGC
AGAGACCCTATTTGGAAAGGACCAGCCAAACTACTCTGGAAAGGTGAAGGGGCAGTA
GTAATACAAGATAATAGTGACATAAAGGTAGTACCAAGGAGAAAAGCAAAAATTATT
AGGGACTATGGAAAACAGATGGCAGGTGCTGATTGTGTGGCAGGTAGACAGGATGAG
GATCAGAACATGGAATAG  
 
Total mismatches: 8 (0.91%) = 99% match 
 
>FV23 
TTTCTAGATGGAATAGACAAGGCTCAAGAAGAGCATGAAAAATACCACAGCAATTGG
AGAGCAATGGCTAATGAGTTTAATCTGCCACCTGTAGTAGCAAAAGAAATAGTAGCTA
GCTGTGATAAATGTCAGTTAAAAGGGGAAGCCATGCATGGACAAGTAGACTGTAGTCC
AGGGATATGGCAATTAGACTGTACACATTTAGAAGGAAAAACCATCTTAGTAGCAGTC
CATGTAGCCAGTGGTTACATAGAAGCAGAGGTTATCCCAGCAGAAACAGGACAGGAA
ACAGCATACTATATACTAAAGCTAGCAGGAAGATGGCCAGTCAAAGTAATACATACA
GACAATGGCAGTAATTTCACCAGTACTGCAGTTAAGGCAGCCTGTTGGTGGGCAGGCA
TCCAACAAGAATTTGGAATTCCCTACAATCCTCAAAGTCAGGGAGTAGTAGAATCCAT
GAATAAAGAACTAAAGAAAATTATAGGGCAGGTAAGAGATCAAGCTGAGCACCTTAA
GACAGCAGTACAAATGGCAGTATTCATTCACAATTTTAAAAGAAAAGGGGGGATTGG
GGGGTACAGTGCAGGGGAAAGAATAATAGACATAATAGCAACAGACATACAAACTAA
AGAACTACAAAAACAAATTATAAAAATTCAAAATTTTCGGGTTTATTACAGAGACAGC
AGAGACCCTATTTGGAAAGGACCAGCCAAACTACTCTGGAAAGGTGAAGGGGCAGTA
GTGATACAAGATAATAGTGACATAAAGGTAGTACCAAGAAGGAAAGCAAAAATTATT
AGGGACTATGGAAAACAGATGGCAGGTGCTGATTGTGTGGCAAGTAGACAGGATGAG
GATCAGAACATGGAATAG  
 
Total mismatches: 6 (0.68%) = 99% match 
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Appendix E: Additional protocols 
RT-LAMP product purification by GeneJet™ PCR purification kit (Thermo Scientific, 
Massachusetts, USA) 
- 1:1 volume of binding buffer (proprietary) was added to LAMP reaction mixture, 
vortexed for 10 seconds, spun down for 10 seconds 
- The solution was applied to the centre of a GeneJet™ purification column and 
centrifuged at 12000xg for 1 minute. 
- Flow-through was discarded and wash buffer (700 µl) (proprietary) added to the 
column and centrifuged at 12000xg for 1 minute. 
- Flow-through was discarded and the column centrifuged dry at 12000xg for 1 
minute. 
- Column was placed in a sterile 1.5 ml eppendorf tube and elution buffer (10 mM 
Tris-HCl) (30 µl) was applied to the column and incubated at ambient temperature 
for 1 minute. 
- The column was centrifuged at 12000xg for 1 minute and the eluate quantified by 
Nanodrop™ Spectrophotometry. 
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Appendix F: Optimised RT-LAMP performed on serial dilutions of patient-derived plasma 
of known viral load concentrations 
In following the optimised RNA extraction procedure (section 3.1), a subset of 10 patient 
samples of known viral loads were collected for later use to aid the determination of the 
time point in the reaction at which a colour change from violet to blue indicates a viral load 
≥ 1000 copies HIV RNA/ml. Following RNA extraction, dilutions of copy numbers were 
tested with the optimised RT-LAMP assay (Fig. F1), however this resulted in non-specific 
amplification (Fig. F1.B, lanes 6-8) and no colour change from violet to blue was produced 
(Figure F1.A). 
 
Table F1 Comparison of HIV-1 viral load and concentration of RNA extracted using the Qiagen 
Viral RNA extraction procedure following SST purification and viral particle concentration of 1ml 
of HIV patient-derived plasma. Concentration determined by Nanodrop™ spectrophotometry. Viral 
load was determined by real-time RT PCR-based routine testing at a centralised viral load 
laboratory.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure F1 RT-LAMP performed on dilutions of HIV-infected plasma-derived RNA to assess 
sensitivity of the viral load assay to distinguish varying viral loads. A) Reaction colour at start (0 
min.) and end (60 min.). B) RT-LAMP reaction products analysed by 2% T.B.E. agarose gel 
electrophoresis. Viral load of the plasma samples was determined by real-time RT-PCR at a routine 
viral load laboratory on replicate plasma samples. The range of HIV copy numbers tested included 
370 000 (1 and 6), 5000 (2), 1000 (3 and 4) and 500 (5 and 7) alongside RT-negative (6 and 7) and 
no template controls (8). MWM: 1Kb DNA ladder.  
Sample ID C (ng/µl) Viral Load 
(copies RNA/ml) 
H16  83.5 245 395 
H13  150.5 140733 
H17   113.7 120 950 
H12   25.7 62774 
H14
 
135.1 14195 
H18  89.46 5810 
